# PeptideScanner evidence objects: Exenatide

Every published version of the records placed with Exenatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/exenatide.json. Selected public evidence only; not medical advice.

- Objects: 121
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00375492-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00375492

> PeptideScanner retained ClinicalTrials.gov record NCT00375492 at 2026-07-30T21:42:40.801Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00375492-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00375492-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00375492-exenatide-v1
- Content SHA-256: `49483638a79b760668415cef5117d658174458275a79fc51a9260c3d6257cbd4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00375492 ([`ctg-observation-nct00375492-2015-04-07-e4cb24204354`](#source-ctg-observation-nct00375492-2015-04-07-e4cb24204354))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00375492 at 2026-07-30T21:42:40.801Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00375492-2015-04-07-e4cb24204354`](#source-ctg-observation-nct00375492-2015-04-07-e4cb24204354))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00375492 at 2026-07-30T21:42:40.801Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00375492-2015-04-07-e4cb24204354`](#source-ctg-observation-nct00375492-2015-04-07-e4cb24204354))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00375492-2015-04-07-e4cb24204354`](#source-ctg-observation-nct00375492-2015-04-07-e4cb24204354))

### Sources

<a id="source-ctg-observation-nct00375492-2015-04-07-e4cb24204354"></a>
- **ClinicalTrials.gov record NCT00375492 · retained source version 2015-04-07:e4cb242043549ffcb5c52727c58b2c195fb958b2d9279a4ad93bb7cd565054c9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00375492) (`ctg-observation-nct00375492-2015-04-07-e4cb24204354`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00375492." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00375492-exenatide-v1 SHA-256: 49483638a79b760668415cef5117d658174458275a79fc51a9260c3d6257cbd4.

---

<a id="clinicaltrials-gov-nct00381342-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00381342

> PeptideScanner retained ClinicalTrials.gov record NCT00381342 at 2026-07-30T21:43:54.470Z. Its registry update date was 2015-02-23, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00381342-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-02-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00381342-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00381342-exenatide-v1
- Content SHA-256: `8b355df533fe002335a594df812f079dbdc6251996da079d744cbeca4c5470b3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00381342 ([`ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c`](#source-ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00381342 at 2026-07-30T21:43:54.470Z. Its registry update date was 2015-02-23, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c`](#source-ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00381342 at 2026-07-30T21:43:54.470Z. Its registry update date was 2015-02-23, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c`](#source-ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c`](#source-ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c))

### Sources

<a id="source-ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c"></a>
- **ClinicalTrials.gov record NCT00381342 · retained source version 2015-02-23:f4981d9e4a7c357891516d9078c5c9ffbc382e27ba9a9949b1c45190e5f5490c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00381342) (`ctg-observation-nct00381342-2015-02-23-f4981d9e4a7c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00381342." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00381342-exenatide-v1 SHA-256: 8b355df533fe002335a594df812f079dbdc6251996da079d744cbeca4c5470b3.

---

<a id="clinicaltrials-gov-nct00456885-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00456885

> PeptideScanner retained ClinicalTrials.gov record NCT00456885 at 2026-07-30T21:23:14.762Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00456885-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00456885-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00456885-exenatide-v1
- Content SHA-256: `f85602947e224791541194faacebdf2f9743caefb9f957dae8b96d2f47188462`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00456885 ([`ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78`](#source-ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00456885 at 2026-07-30T21:23:14.762Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78`](#source-ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00456885 at 2026-07-30T21:23:14.762Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78`](#source-ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78`](#source-ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78))

### Sources

<a id="source-ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78"></a>
- **ClinicalTrials.gov record NCT00456885 · retained source version 2017-09-11:f9bcb3c24c781e59ac8d544a4c30204e78cd5a09a1a3a285ecb453d9034a460e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00456885) (`ctg-observation-nct00456885-2017-09-11-f9bcb3c24c78`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00456885." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00456885-exenatide-v1 SHA-256: f85602947e224791541194faacebdf2f9743caefb9f957dae8b96d2f47188462.

---

<a id="clinicaltrials-gov-nct00500370-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00500370

> PeptideScanner retained ClinicalTrials.gov record NCT00500370 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00500370-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00500370-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00500370-exenatide-v1
- Content SHA-256: `7cb732b7df10c7f0d9525713b5abf796349879e51291a560fc899f493e6c8461`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00500370 ([`ctg-observation-nct00500370-2015-04-07-71a18a2f2d33`](#source-ctg-observation-nct00500370-2015-04-07-71a18a2f2d33))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00500370 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00500370-2015-04-07-71a18a2f2d33`](#source-ctg-observation-nct00500370-2015-04-07-71a18a2f2d33))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00500370 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00500370-2015-04-07-71a18a2f2d33`](#source-ctg-observation-nct00500370-2015-04-07-71a18a2f2d33))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00500370-2015-04-07-71a18a2f2d33`](#source-ctg-observation-nct00500370-2015-04-07-71a18a2f2d33))

### Sources

<a id="source-ctg-observation-nct00500370-2015-04-07-71a18a2f2d33"></a>
- **ClinicalTrials.gov record NCT00500370 · retained source version 2015-04-07:71a18a2f2d33ea9eed0b04d2b43855b988cdd928f8cfc0b742d50420468b1ac8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00500370) (`ctg-observation-nct00500370-2015-04-07-71a18a2f2d33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00500370." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00500370-exenatide-v1 SHA-256: 7cb732b7df10c7f0d9525713b5abf796349879e51291a560fc899f493e6c8461.

---

<a id="clinicaltrials-gov-nct00546728-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00546728

> PeptideScanner retained ClinicalTrials.gov record NCT00546728 at 2026-07-30T21:55:56.615Z. Its registry update date was 2013-11-08, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00546728-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-11-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00546728-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00546728-exenatide-v1
- Content SHA-256: `a05b090b6aca1b5f272d7e2713543b66d3af8e266422d6ee99212630eeb558ee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00546728 ([`ctg-observation-nct00546728-2013-11-08-615ec545ddd9`](#source-ctg-observation-nct00546728-2013-11-08-615ec545ddd9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00546728 at 2026-07-30T21:55:56.615Z. Its registry update date was 2013-11-08, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00546728-2013-11-08-615ec545ddd9`](#source-ctg-observation-nct00546728-2013-11-08-615ec545ddd9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00546728 at 2026-07-30T21:55:56.615Z. Its registry update date was 2013-11-08, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00546728-2013-11-08-615ec545ddd9`](#source-ctg-observation-nct00546728-2013-11-08-615ec545ddd9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00546728-2013-11-08-615ec545ddd9`](#source-ctg-observation-nct00546728-2013-11-08-615ec545ddd9))

### Sources

<a id="source-ctg-observation-nct00546728-2013-11-08-615ec545ddd9"></a>
- **ClinicalTrials.gov record NCT00546728 · retained source version 2013-11-08:615ec545ddd9d7f4578956ef841fc81c4d254a66eec6b372ed81fc1bcf368cdb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00546728) (`ctg-observation-nct00546728-2013-11-08-615ec545ddd9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00546728." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00546728-exenatide-v1 SHA-256: a05b090b6aca1b5f272d7e2713543b66d3af8e266422d6ee99212630eeb558ee.

---

<a id="clinicaltrials-gov-nct00551343-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00551343

> PeptideScanner retained ClinicalTrials.gov record NCT00551343 at 2026-07-30T20:25:27.243Z. Its registry update date was 2020-07-07, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00551343-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-07-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00551343-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00551343-exenatide-v1
- Content SHA-256: `0b29ef6ffca2421d502361608daa5cfee4da13a4bcd580235c1052fdeab001cb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00551343 ([`ctg-observation-nct00551343-2020-07-07-5b389c4986d0`](#source-ctg-observation-nct00551343-2020-07-07-5b389c4986d0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00551343 at 2026-07-30T20:25:27.243Z. Its registry update date was 2020-07-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00551343-2020-07-07-5b389c4986d0`](#source-ctg-observation-nct00551343-2020-07-07-5b389c4986d0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00551343 at 2026-07-30T20:25:27.243Z. Its registry update date was 2020-07-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00551343-2020-07-07-5b389c4986d0`](#source-ctg-observation-nct00551343-2020-07-07-5b389c4986d0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00551343-2020-07-07-5b389c4986d0`](#source-ctg-observation-nct00551343-2020-07-07-5b389c4986d0))

### Sources

<a id="source-ctg-observation-nct00551343-2020-07-07-5b389c4986d0"></a>
- **ClinicalTrials.gov record NCT00551343 · retained source version 2020-07-07:5b389c4986d0439f18f19d19d9db24bc568552ae71dddc6ceae42e539ac9c0ca** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00551343) (`ctg-observation-nct00551343-2020-07-07-5b389c4986d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00551343." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00551343-exenatide-v1 SHA-256: 0b29ef6ffca2421d502361608daa5cfee4da13a4bcd580235c1052fdeab001cb.

---

<a id="clinicaltrials-gov-nct00650546-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00650546

> PeptideScanner retained ClinicalTrials.gov record NCT00650546 at 2026-07-30T21:24:24.230Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00650546-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00650546-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00650546-exenatide-v1
- Content SHA-256: `21642efe3b9f72329481853256e1ebddf2f460d729626533125c040f60f0ef16`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00650546 ([`ctg-observation-nct00650546-2017-04-11-f35cb54eb518`](#source-ctg-observation-nct00650546-2017-04-11-f35cb54eb518))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00650546 at 2026-07-30T21:24:24.230Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00650546-2017-04-11-f35cb54eb518`](#source-ctg-observation-nct00650546-2017-04-11-f35cb54eb518))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00650546 at 2026-07-30T21:24:24.230Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00650546-2017-04-11-f35cb54eb518`](#source-ctg-observation-nct00650546-2017-04-11-f35cb54eb518))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00650546-2017-04-11-f35cb54eb518`](#source-ctg-observation-nct00650546-2017-04-11-f35cb54eb518))

### Sources

<a id="source-ctg-observation-nct00650546-2017-04-11-f35cb54eb518"></a>
- **ClinicalTrials.gov record NCT00650546 · retained source version 2017-04-11:f35cb54eb518630a72f0c94b37a6ee84efbaa6cf79010b76aab7f94d4db9929d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00650546) (`ctg-observation-nct00650546-2017-04-11-f35cb54eb518`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00650546." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00650546-exenatide-v1 SHA-256: 21642efe3b9f72329481853256e1ebddf2f460d729626533125c040f60f0ef16.

---

<a id="clinicaltrials-gov-nct00775684-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00775684

> PeptideScanner retained ClinicalTrials.gov record NCT00775684 at 2026-07-30T19:38:43.099Z. Its registry update date was 2022-06-07, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00775684-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00775684-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00775684-exenatide-v1
- Content SHA-256: `80a56b50d838465b0efb2fb6a851ff6e8f1d21373927c50a07264e8445d68acd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00775684 ([`ctg-observation-nct00775684-2022-06-07-2b2afcd80099`](#source-ctg-observation-nct00775684-2022-06-07-2b2afcd80099))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00775684 at 2026-07-30T19:38:43.099Z. Its registry update date was 2022-06-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00775684-2022-06-07-2b2afcd80099`](#source-ctg-observation-nct00775684-2022-06-07-2b2afcd80099))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00775684 at 2026-07-30T19:38:43.099Z. Its registry update date was 2022-06-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00775684-2022-06-07-2b2afcd80099`](#source-ctg-observation-nct00775684-2022-06-07-2b2afcd80099))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00775684-2022-06-07-2b2afcd80099`](#source-ctg-observation-nct00775684-2022-06-07-2b2afcd80099))

### Sources

<a id="source-ctg-observation-nct00775684-2022-06-07-2b2afcd80099"></a>
- **ClinicalTrials.gov record NCT00775684 · retained source version 2022-06-07:2b2afcd80099346da8cdb6e380ec9baeacfb1f2d25d7f19f76944a11fcf8bc7c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00775684) (`ctg-observation-nct00775684-2022-06-07-2b2afcd80099`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00775684." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00775684-exenatide-v1 SHA-256: 80a56b50d838465b0efb2fb6a851ff6e8f1d21373927c50a07264e8445d68acd.

---

<a id="clinicaltrials-gov-nct00835848-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00835848

> PeptideScanner retained ClinicalTrials.gov record NCT00835848 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-05, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00835848-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-05-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00835848-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00835848-exenatide-v1
- Content SHA-256: `a7141596568d93250ca654bf6dfc0da83f6fba1bbe2808066595ed8977f0ce40`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00835848 ([`ctg-observation-nct00835848-2015-05-05-9f74b2dc098b`](#source-ctg-observation-nct00835848-2015-05-05-9f74b2dc098b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00835848 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-05, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00835848-2015-05-05-9f74b2dc098b`](#source-ctg-observation-nct00835848-2015-05-05-9f74b2dc098b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00835848 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-05, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00835848-2015-05-05-9f74b2dc098b`](#source-ctg-observation-nct00835848-2015-05-05-9f74b2dc098b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00835848-2015-05-05-9f74b2dc098b`](#source-ctg-observation-nct00835848-2015-05-05-9f74b2dc098b))

### Sources

<a id="source-ctg-observation-nct00835848-2015-05-05-9f74b2dc098b"></a>
- **ClinicalTrials.gov record NCT00835848 · retained source version 2015-05-05:9f74b2dc098b214dbee37cc9ef2c3d51cc27c3c92e37d2a8e7d0a3c3ba8d44ea** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00835848) (`ctg-observation-nct00835848-2015-05-05-9f74b2dc098b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00835848." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00835848-exenatide-v1 SHA-256: a7141596568d93250ca654bf6dfc0da83f6fba1bbe2808066595ed8977f0ce40.

---

<a id="clinicaltrials-gov-nct00845182-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00845182

> PeptideScanner retained ClinicalTrials.gov record NCT00845182 at 2026-07-30T21:12:47.410Z. Its registry update date was 2018-01-18, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00845182-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00845182-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00845182-exenatide-v1
- Content SHA-256: `abce13571d56efd6841ffd8900b2f3664b366b10977c6ad4b89f2cb3bb3cb1d1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00845182 ([`ctg-observation-nct00845182-2018-01-18-cbde83a38a7a`](#source-ctg-observation-nct00845182-2018-01-18-cbde83a38a7a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00845182 at 2026-07-30T21:12:47.410Z. Its registry update date was 2018-01-18, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00845182-2018-01-18-cbde83a38a7a`](#source-ctg-observation-nct00845182-2018-01-18-cbde83a38a7a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00845182 at 2026-07-30T21:12:47.410Z. Its registry update date was 2018-01-18, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00845182-2018-01-18-cbde83a38a7a`](#source-ctg-observation-nct00845182-2018-01-18-cbde83a38a7a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00845182-2018-01-18-cbde83a38a7a`](#source-ctg-observation-nct00845182-2018-01-18-cbde83a38a7a))

### Sources

<a id="source-ctg-observation-nct00845182-2018-01-18-cbde83a38a7a"></a>
- **ClinicalTrials.gov record NCT00845182 · retained source version 2018-01-18:cbde83a38a7ad8a96e829a5f36962d44617fb9468b91a43ec3f3bcea454d34d6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00845182) (`ctg-observation-nct00845182-2018-01-18-cbde83a38a7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00845182." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00845182-exenatide-v1 SHA-256: abce13571d56efd6841ffd8900b2f3664b366b10977c6ad4b89f2cb3bb3cb1d1.

---

<a id="clinicaltrials-gov-nct00845507-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00845507

> PeptideScanner retained ClinicalTrials.gov record NCT00845507 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-04-20, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00845507-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-04-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00845507-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00845507-exenatide-v1
- Content SHA-256: `a6c8ad2a48c93f9929b786ad499185b50ae8df0235d8d06f4f12df217a2d1423`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00845507 ([`ctg-observation-nct00845507-2018-04-20-9c0942df52af`](#source-ctg-observation-nct00845507-2018-04-20-9c0942df52af))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00845507 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-04-20, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00845507-2018-04-20-9c0942df52af`](#source-ctg-observation-nct00845507-2018-04-20-9c0942df52af))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00845507 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-04-20, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00845507-2018-04-20-9c0942df52af`](#source-ctg-observation-nct00845507-2018-04-20-9c0942df52af))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00845507-2018-04-20-9c0942df52af`](#source-ctg-observation-nct00845507-2018-04-20-9c0942df52af))

### Sources

<a id="source-ctg-observation-nct00845507-2018-04-20-9c0942df52af"></a>
- **ClinicalTrials.gov record NCT00845507 · retained source version 2018-04-20:9c0942df52afce5c82b79ba49084d3e2945c31614c3556c5acd044b5bb6fe61f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00845507) (`ctg-observation-nct00845507-2018-04-20-9c0942df52af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00845507." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00845507-exenatide-v1 SHA-256: a6c8ad2a48c93f9929b786ad499185b50ae8df0235d8d06f4f12df217a2d1423.

---

<a id="clinicaltrials-gov-nct00855439-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00855439

> PeptideScanner retained ClinicalTrials.gov record NCT00855439 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00855439-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00855439-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00855439-exenatide-v1
- Content SHA-256: `f1137ccdb4ebe975ccaf6e429ebe929f72bd66eb995d0aabfc32bae08fe334e8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00855439 ([`ctg-observation-nct00855439-2017-03-01-7005c26eed86`](#source-ctg-observation-nct00855439-2017-03-01-7005c26eed86))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00855439 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00855439-2017-03-01-7005c26eed86`](#source-ctg-observation-nct00855439-2017-03-01-7005c26eed86))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00855439 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00855439-2017-03-01-7005c26eed86`](#source-ctg-observation-nct00855439-2017-03-01-7005c26eed86))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00855439-2017-03-01-7005c26eed86`](#source-ctg-observation-nct00855439-2017-03-01-7005c26eed86))

### Sources

<a id="source-ctg-observation-nct00855439-2017-03-01-7005c26eed86"></a>
- **ClinicalTrials.gov record NCT00855439 · retained source version 2017-03-01:7005c26eed8623cc31457d7da32e61f9b7e9a0e65e89d20c6219c868c0e6afbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00855439) (`ctg-observation-nct00855439-2017-03-01-7005c26eed86`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00855439." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00855439-exenatide-v1 SHA-256: f1137ccdb4ebe975ccaf6e429ebe929f72bd66eb995d0aabfc32bae08fe334e8.

---

<a id="clinicaltrials-gov-nct00974272-exenatide-v1"></a>

## ClinicalTrials.gov record NCT00974272

> PeptideScanner retained ClinicalTrials.gov record NCT00974272 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-09-10, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct00974272-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-09-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00974272-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00974272-exenatide-v1
- Content SHA-256: `fed3fa2877ce05ac0e6c11f6b0ee69d14a36290bbb8804f1155d837569238c07`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00974272 ([`ctg-observation-nct00974272-2009-09-10-7518019b521d`](#source-ctg-observation-nct00974272-2009-09-10-7518019b521d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00974272 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-09-10, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00974272-2009-09-10-7518019b521d`](#source-ctg-observation-nct00974272-2009-09-10-7518019b521d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00974272 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-09-10, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct00974272-2009-09-10-7518019b521d`](#source-ctg-observation-nct00974272-2009-09-10-7518019b521d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00974272-2009-09-10-7518019b521d`](#source-ctg-observation-nct00974272-2009-09-10-7518019b521d))

### Sources

<a id="source-ctg-observation-nct00974272-2009-09-10-7518019b521d"></a>
- **ClinicalTrials.gov record NCT00974272 · retained source version 2009-09-10:7518019b521dcea2fdb89ec6f101c04a03031c4f88c2b54ece64cfb7297b6094** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00974272) (`ctg-observation-nct00974272-2009-09-10-7518019b521d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00974272." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct00974272-exenatide-v1 SHA-256: fed3fa2877ce05ac0e6c11f6b0ee69d14a36290bbb8804f1155d837569238c07.

---

<a id="clinicaltrials-gov-nct01046721-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01046721

> PeptideScanner retained ClinicalTrials.gov record NCT01046721 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-03-06, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01046721-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-03-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01046721-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01046721-exenatide-v1
- Content SHA-256: `a6547ae9e1fa8e61b07138cdf9e50e41a318b511eff8805f25771ebb6558149f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01046721 ([`ctg-observation-nct01046721-2018-03-06-22450e04086a`](#source-ctg-observation-nct01046721-2018-03-06-22450e04086a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01046721 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-03-06, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01046721-2018-03-06-22450e04086a`](#source-ctg-observation-nct01046721-2018-03-06-22450e04086a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01046721 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-03-06, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01046721-2018-03-06-22450e04086a`](#source-ctg-observation-nct01046721-2018-03-06-22450e04086a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01046721-2018-03-06-22450e04086a`](#source-ctg-observation-nct01046721-2018-03-06-22450e04086a))

### Sources

<a id="source-ctg-observation-nct01046721-2018-03-06-22450e04086a"></a>
- **ClinicalTrials.gov record NCT01046721 · retained source version 2018-03-06:22450e04086a90a6d034b5d21930a5d615e6aa442fa02b68dc2ed15e83d51975** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01046721) (`ctg-observation-nct01046721-2018-03-06-22450e04086a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01046721." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01046721-exenatide-v1 SHA-256: a6547ae9e1fa8e61b07138cdf9e50e41a318b511eff8805f25771ebb6558149f.

---

<a id="clinicaltrials-gov-nct01056549-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01056549

> PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01056549-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01056549-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01056549-exenatide-v1
- Content SHA-256: `0d76dd6b544f36237e4e1934f7f5bbd8f000e5e2879945d9aca3e07f22728736`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01056549 ([`ctg-observation-nct01056549-2012-06-22-7854afd1ecbf`](#source-ctg-observation-nct01056549-2012-06-22-7854afd1ecbf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01056549-2012-06-22-7854afd1ecbf`](#source-ctg-observation-nct01056549-2012-06-22-7854afd1ecbf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01056549-2012-06-22-7854afd1ecbf`](#source-ctg-observation-nct01056549-2012-06-22-7854afd1ecbf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01056549-2012-06-22-7854afd1ecbf`](#source-ctg-observation-nct01056549-2012-06-22-7854afd1ecbf))

### Sources

<a id="source-ctg-observation-nct01056549-2012-06-22-7854afd1ecbf"></a>
- **ClinicalTrials.gov record NCT01056549 · retained source version 2012-06-22:7854afd1ecbff9052805900c2185051df725b87e50b79ee1c3788d2e4b7b58c1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01056549) (`ctg-observation-nct01056549-2012-06-22-7854afd1ecbf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01056549." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01056549-exenatide-v1 SHA-256: 0d76dd6b544f36237e4e1934f7f5bbd8f000e5e2879945d9aca3e07f22728736.

---

<a id="clinicaltrials-gov-nct01061775-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01061775

> PeptideScanner retained ClinicalTrials.gov record NCT01061775 at 2026-07-30T20:44:36.699Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01061775-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01061775-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01061775-exenatide-v1
- Content SHA-256: `249863ac74e50e482e2a3ace4eaa724f94c0312aafb965f4dcd89ac1b5bac559`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01061775 ([`ctg-observation-nct01061775-2019-10-08-217c5edc721c`](#source-ctg-observation-nct01061775-2019-10-08-217c5edc721c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01061775 at 2026-07-30T20:44:36.699Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01061775-2019-10-08-217c5edc721c`](#source-ctg-observation-nct01061775-2019-10-08-217c5edc721c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01061775 at 2026-07-30T20:44:36.699Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01061775-2019-10-08-217c5edc721c`](#source-ctg-observation-nct01061775-2019-10-08-217c5edc721c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01061775-2019-10-08-217c5edc721c`](#source-ctg-observation-nct01061775-2019-10-08-217c5edc721c))

### Sources

<a id="source-ctg-observation-nct01061775-2019-10-08-217c5edc721c"></a>
- **ClinicalTrials.gov record NCT01061775 · retained source version 2019-10-08:217c5edc721c60b6fa23a4deb261335ea9d3d1e3bd06f09b162d84d9b489543b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01061775) (`ctg-observation-nct01061775-2019-10-08-217c5edc721c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01061775." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01061775-exenatide-v1 SHA-256: 249863ac74e50e482e2a3ace4eaa724f94c0312aafb965f4dcd89ac1b5bac559.

---

<a id="clinicaltrials-gov-nct01077323-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01077323

> PeptideScanner retained ClinicalTrials.gov record NCT01077323 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01077323-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01077323-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01077323-exenatide-v1
- Content SHA-256: `14549a395797999b23767b6dd75e3eda91ac101cb33a49c4cdc071fba831b184`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01077323 ([`ctg-observation-nct01077323-2015-04-15-3977f46cf23d`](#source-ctg-observation-nct01077323-2015-04-15-3977f46cf23d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01077323 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01077323-2015-04-15-3977f46cf23d`](#source-ctg-observation-nct01077323-2015-04-15-3977f46cf23d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01077323 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01077323-2015-04-15-3977f46cf23d`](#source-ctg-observation-nct01077323-2015-04-15-3977f46cf23d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01077323-2015-04-15-3977f46cf23d`](#source-ctg-observation-nct01077323-2015-04-15-3977f46cf23d))

### Sources

<a id="source-ctg-observation-nct01077323-2015-04-15-3977f46cf23d"></a>
- **ClinicalTrials.gov record NCT01077323 · retained source version 2015-04-15:3977f46cf23d3f285908022cad25fa8b6b6c9d820bf19430672506209639535f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01077323) (`ctg-observation-nct01077323-2015-04-15-3977f46cf23d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01077323." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01077323-exenatide-v1 SHA-256: 14549a395797999b23767b6dd75e3eda91ac101cb33a49c4cdc071fba831b184.

---

<a id="clinicaltrials-gov-nct01208649-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01208649

> PeptideScanner retained ClinicalTrials.gov record NCT01208649 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-09-24, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01208649-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-09-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01208649-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01208649-exenatide-v1
- Content SHA-256: `eab33b2787a109144f75edf771df61f586623ace29d5828427c594a5142962af`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01208649 ([`ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b`](#source-ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01208649 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-09-24, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b`](#source-ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01208649 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-09-24, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b`](#source-ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b`](#source-ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b))

### Sources

<a id="source-ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b"></a>
- **ClinicalTrials.gov record NCT01208649 · retained source version 2010-09-24:8a0d2facdf8b5ffec91dbbc0c4b406185f832955c51b1ab3f19b1fe1c8bd4211** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01208649) (`ctg-observation-nct01208649-2010-09-24-8a0d2facdf8b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01208649." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01208649-exenatide-v1 SHA-256: eab33b2787a109144f75edf771df61f586623ace29d5828427c594a5142962af.

---

<a id="clinicaltrials-gov-nct01237197-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01237197

> PeptideScanner retained ClinicalTrials.gov record NCT01237197 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01237197-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-09-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01237197-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01237197-exenatide-v1
- Content SHA-256: `561b80cff26cc7de2820a1634f91a7cb7e085ac5c3ed42fafd170f62a147f58d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01237197 ([`ctg-observation-nct01237197-2014-09-12-394daf05fbfd`](#source-ctg-observation-nct01237197-2014-09-12-394daf05fbfd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01237197 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01237197-2014-09-12-394daf05fbfd`](#source-ctg-observation-nct01237197-2014-09-12-394daf05fbfd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01237197 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01237197-2014-09-12-394daf05fbfd`](#source-ctg-observation-nct01237197-2014-09-12-394daf05fbfd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01237197-2014-09-12-394daf05fbfd`](#source-ctg-observation-nct01237197-2014-09-12-394daf05fbfd))

### Sources

<a id="source-ctg-observation-nct01237197-2014-09-12-394daf05fbfd"></a>
- **ClinicalTrials.gov record NCT01237197 · retained source version 2014-09-12:394daf05fbfd0e2713e42fb3017a58c872d7595f86d50f869108cbaafa4f2b58** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01237197) (`ctg-observation-nct01237197-2014-09-12-394daf05fbfd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01237197." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01237197-exenatide-v1 SHA-256: 561b80cff26cc7de2820a1634f91a7cb7e085ac5c3ed42fafd170f62a147f58d.

---

<a id="clinicaltrials-gov-nct01297062-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01297062

> PeptideScanner retained ClinicalTrials.gov record NCT01297062 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01297062-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01297062-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01297062-exenatide-v1
- Content SHA-256: `0551ba3055d5e58f582d13d4c567de26596139157ec595464a67d6e2fc387349`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01297062 ([`ctg-observation-nct01297062-2015-04-14-c60f48d33099`](#source-ctg-observation-nct01297062-2015-04-14-c60f48d33099))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01297062 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01297062-2015-04-14-c60f48d33099`](#source-ctg-observation-nct01297062-2015-04-14-c60f48d33099))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01297062 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01297062-2015-04-14-c60f48d33099`](#source-ctg-observation-nct01297062-2015-04-14-c60f48d33099))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01297062-2015-04-14-c60f48d33099`](#source-ctg-observation-nct01297062-2015-04-14-c60f48d33099))

### Sources

<a id="source-ctg-observation-nct01297062-2015-04-14-c60f48d33099"></a>
- **ClinicalTrials.gov record NCT01297062 · retained source version 2015-04-14:c60f48d3309978957ee07fb507187eb80ae8beacac12ad52647883257c009db7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01297062) (`ctg-observation-nct01297062-2015-04-14-c60f48d33099`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01297062." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01297062-exenatide-v1 SHA-256: 0551ba3055d5e58f582d13d4c567de26596139157ec595464a67d6e2fc387349.

---

<a id="clinicaltrials-gov-nct01364584-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01364584

> PeptideScanner retained ClinicalTrials.gov record NCT01364584 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-12, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01364584-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01364584-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01364584-exenatide-v1
- Content SHA-256: `37e0253b743d98187e0659316e343f7cd4ef14aa00311bb9df6b4d63286170a3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01364584 ([`ctg-observation-nct01364584-2023-07-12-39549cb1bc22`](#source-ctg-observation-nct01364584-2023-07-12-39549cb1bc22))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01364584 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-12, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01364584-2023-07-12-39549cb1bc22`](#source-ctg-observation-nct01364584-2023-07-12-39549cb1bc22))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01364584 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-12, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01364584-2023-07-12-39549cb1bc22`](#source-ctg-observation-nct01364584-2023-07-12-39549cb1bc22))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01364584-2023-07-12-39549cb1bc22`](#source-ctg-observation-nct01364584-2023-07-12-39549cb1bc22))

### Sources

<a id="source-ctg-observation-nct01364584-2023-07-12-39549cb1bc22"></a>
- **ClinicalTrials.gov record NCT01364584 · retained source version 2023-07-12:39549cb1bc22f8643d89627c687bda8874b2e22d120cbb74b080d7f8ca389991** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01364584) (`ctg-observation-nct01364584-2023-07-12-39549cb1bc22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01364584." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01364584-exenatide-v1 SHA-256: 37e0253b743d98187e0659316e343f7cd4ef14aa00311bb9df6b4d63286170a3.

---

<a id="clinicaltrials-gov-nct01416649-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01416649

> PeptideScanner retained ClinicalTrials.gov record NCT01416649 at 2026-07-30T19:14:02.187Z. Its registry update date was 2023-04-26, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01416649-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-04-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01416649-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01416649-exenatide-v1
- Content SHA-256: `b27bf66cf6e9f1cc749955345903e21a7c29bc3fe08e0b802a997ae2dfa2bad9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01416649 ([`ctg-observation-nct01416649-2023-04-26-b67672b6a977`](#source-ctg-observation-nct01416649-2023-04-26-b67672b6a977))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01416649 at 2026-07-30T19:14:02.187Z. Its registry update date was 2023-04-26, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01416649-2023-04-26-b67672b6a977`](#source-ctg-observation-nct01416649-2023-04-26-b67672b6a977))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01416649 at 2026-07-30T19:14:02.187Z. Its registry update date was 2023-04-26, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01416649-2023-04-26-b67672b6a977`](#source-ctg-observation-nct01416649-2023-04-26-b67672b6a977))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01416649-2023-04-26-b67672b6a977`](#source-ctg-observation-nct01416649-2023-04-26-b67672b6a977))

### Sources

<a id="source-ctg-observation-nct01416649-2023-04-26-b67672b6a977"></a>
- **ClinicalTrials.gov record NCT01416649 · retained source version 2023-04-26:b67672b6a9773a9de150d2acc81e121bfff3aecae7907c4ec7afda0d37c768d1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01416649) (`ctg-observation-nct01416649-2023-04-26-b67672b6a977`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01416649." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01416649-exenatide-v1 SHA-256: b27bf66cf6e9f1cc749955345903e21a7c29bc3fe08e0b802a997ae2dfa2bad9.

---

<a id="clinicaltrials-gov-nct01432405-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01432405

> PeptideScanner retained ClinicalTrials.gov record NCT01432405 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01432405-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01432405-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01432405-exenatide-v1
- Content SHA-256: `c7b8e4dc5107ebe17d6646f847b687313c633f7da89e0b012241277b563b1c55`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01432405 ([`ctg-observation-nct01432405-2016-04-12-a2aaded295de`](#source-ctg-observation-nct01432405-2016-04-12-a2aaded295de))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01432405 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01432405-2016-04-12-a2aaded295de`](#source-ctg-observation-nct01432405-2016-04-12-a2aaded295de))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01432405 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01432405-2016-04-12-a2aaded295de`](#source-ctg-observation-nct01432405-2016-04-12-a2aaded295de))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01432405-2016-04-12-a2aaded295de`](#source-ctg-observation-nct01432405-2016-04-12-a2aaded295de))

### Sources

<a id="source-ctg-observation-nct01432405-2016-04-12-a2aaded295de"></a>
- **ClinicalTrials.gov record NCT01432405 · retained source version 2016-04-12:a2aaded295dec60a4aaf71db300cd8412b4886e4f407d6569279eec50f7c5a57** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01432405) (`ctg-observation-nct01432405-2016-04-12-a2aaded295de`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01432405." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01432405-exenatide-v1 SHA-256: c7b8e4dc5107ebe17d6646f847b687313c633f7da89e0b012241277b563b1c55.

---

<a id="clinicaltrials-gov-nct01444898-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01444898

> PeptideScanner retained ClinicalTrials.gov record NCT01444898 at 2026-07-30T21:36:16.906Z. Its registry update date was 2016-09-29, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01444898-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-09-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01444898-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01444898-exenatide-v1
- Content SHA-256: `051229f8e5e8164716093eaea5a0fb544720fd43d5fd162ad3ea734a2e063755`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01444898 ([`ctg-observation-nct01444898-2016-09-29-3e252c58b626`](#source-ctg-observation-nct01444898-2016-09-29-3e252c58b626))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01444898 at 2026-07-30T21:36:16.906Z. Its registry update date was 2016-09-29, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01444898-2016-09-29-3e252c58b626`](#source-ctg-observation-nct01444898-2016-09-29-3e252c58b626))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01444898 at 2026-07-30T21:36:16.906Z. Its registry update date was 2016-09-29, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01444898-2016-09-29-3e252c58b626`](#source-ctg-observation-nct01444898-2016-09-29-3e252c58b626))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01444898-2016-09-29-3e252c58b626`](#source-ctg-observation-nct01444898-2016-09-29-3e252c58b626))

### Sources

<a id="source-ctg-observation-nct01444898-2016-09-29-3e252c58b626"></a>
- **ClinicalTrials.gov record NCT01444898 · retained source version 2016-09-29:3e252c58b62668a694bad3f1447534c3fe6d5ec3ef315b6f6499ccf93ebe636f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01444898) (`ctg-observation-nct01444898-2016-09-29-3e252c58b626`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01444898." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01444898-exenatide-v1 SHA-256: 051229f8e5e8164716093eaea5a0fb544720fd43d5fd162ad3ea734a2e063755.

---

<a id="clinicaltrials-gov-nct01484873-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01484873

> PeptideScanner retained ClinicalTrials.gov record NCT01484873 at 2026-07-30T21:25:36.820Z. Its registry update date was 2017-03-03, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01484873-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01484873-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01484873-exenatide-v1
- Content SHA-256: `83e4587b271b0c845c7f854cf6143a4c5f984d60d89bec76b378731ae1cb8914`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01484873 ([`ctg-observation-nct01484873-2017-03-03-39af30792020`](#source-ctg-observation-nct01484873-2017-03-03-39af30792020))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01484873 at 2026-07-30T21:25:36.820Z. Its registry update date was 2017-03-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01484873-2017-03-03-39af30792020`](#source-ctg-observation-nct01484873-2017-03-03-39af30792020))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01484873 at 2026-07-30T21:25:36.820Z. Its registry update date was 2017-03-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01484873-2017-03-03-39af30792020`](#source-ctg-observation-nct01484873-2017-03-03-39af30792020))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01484873-2017-03-03-39af30792020`](#source-ctg-observation-nct01484873-2017-03-03-39af30792020))

### Sources

<a id="source-ctg-observation-nct01484873-2017-03-03-39af30792020"></a>
- **ClinicalTrials.gov record NCT01484873 · retained source version 2017-03-03:39af30792020b95a6e017ab90b21a7c947787262c19e201ec1c01cfccd1eae7b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01484873) (`ctg-observation-nct01484873-2017-03-03-39af30792020`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01484873." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01484873-exenatide-v1 SHA-256: 83e4587b271b0c845c7f854cf6143a4c5f984d60d89bec76b378731ae1cb8914.

---

<a id="clinicaltrials-gov-nct01524705-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01524705

> PeptideScanner retained ClinicalTrials.gov record NCT01524705 at 2026-07-30T19:03:45.487Z. Its registry update date was 2023-12-29, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01524705-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-12-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01524705-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01524705-exenatide-v1
- Content SHA-256: `593d4fb080d91a28f5bbd9901cbce328d2c3cc1e9c545bdbde415a736c4d3d9d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01524705 ([`ctg-observation-nct01524705-2023-12-29-6156cb47a64d`](#source-ctg-observation-nct01524705-2023-12-29-6156cb47a64d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01524705 at 2026-07-30T19:03:45.487Z. Its registry update date was 2023-12-29, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01524705-2023-12-29-6156cb47a64d`](#source-ctg-observation-nct01524705-2023-12-29-6156cb47a64d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01524705 at 2026-07-30T19:03:45.487Z. Its registry update date was 2023-12-29, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01524705-2023-12-29-6156cb47a64d`](#source-ctg-observation-nct01524705-2023-12-29-6156cb47a64d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01524705-2023-12-29-6156cb47a64d`](#source-ctg-observation-nct01524705-2023-12-29-6156cb47a64d))

### Sources

<a id="source-ctg-observation-nct01524705-2023-12-29-6156cb47a64d"></a>
- **ClinicalTrials.gov record NCT01524705 · retained source version 2023-12-29:6156cb47a64d712f6d5b831c269d2e06248288d5b2f1368296d2d219897bf42d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01524705) (`ctg-observation-nct01524705-2023-12-29-6156cb47a64d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01524705." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01524705-exenatide-v1 SHA-256: 593d4fb080d91a28f5bbd9901cbce328d2c3cc1e9c545bdbde415a736c4d3d9d.

---

<a id="clinicaltrials-gov-nct01580514-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01580514

> PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01580514-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-04-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01580514-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01580514-exenatide-v1
- Content SHA-256: `6d879bbd53065857f6d5ec614dd660779a42d8e63faddd8622252260d3c41f6f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01580514 ([`ctg-observation-nct01580514-2012-04-19-c965eb338f5a`](#source-ctg-observation-nct01580514-2012-04-19-c965eb338f5a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01580514-2012-04-19-c965eb338f5a`](#source-ctg-observation-nct01580514-2012-04-19-c965eb338f5a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01580514-2012-04-19-c965eb338f5a`](#source-ctg-observation-nct01580514-2012-04-19-c965eb338f5a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01580514-2012-04-19-c965eb338f5a`](#source-ctg-observation-nct01580514-2012-04-19-c965eb338f5a))

### Sources

<a id="source-ctg-observation-nct01580514-2012-04-19-c965eb338f5a"></a>
- **ClinicalTrials.gov record NCT01580514 · retained source version 2012-04-19:c965eb338f5a605c669b28a88063001c28aab9f899053e515312819c1490266e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01580514) (`ctg-observation-nct01580514-2012-04-19-c965eb338f5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01580514." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01580514-exenatide-v1 SHA-256: 6d879bbd53065857f6d5ec614dd660779a42d8e63faddd8622252260d3c41f6f.

---

<a id="clinicaltrials-gov-nct01588418-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01588418

> PeptideScanner retained ClinicalTrials.gov record NCT01588418 at 2026-07-30T21:22:00.248Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01588418-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01588418-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01588418-exenatide-v1
- Content SHA-256: `740ef9481259738213d2db2f5541ee66f92b2ae7bd7b74e632b76565dab9914c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01588418 ([`ctg-observation-nct01588418-2017-11-24-0063b9663288`](#source-ctg-observation-nct01588418-2017-11-24-0063b9663288))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01588418 at 2026-07-30T21:22:00.248Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01588418-2017-11-24-0063b9663288`](#source-ctg-observation-nct01588418-2017-11-24-0063b9663288))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01588418 at 2026-07-30T21:22:00.248Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01588418-2017-11-24-0063b9663288`](#source-ctg-observation-nct01588418-2017-11-24-0063b9663288))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01588418-2017-11-24-0063b9663288`](#source-ctg-observation-nct01588418-2017-11-24-0063b9663288))

### Sources

<a id="source-ctg-observation-nct01588418-2017-11-24-0063b9663288"></a>
- **ClinicalTrials.gov record NCT01588418 · retained source version 2017-11-24:0063b9663288bfc862401444e6609d2aabfba7489694e8d8d57bce6ef1abf7a6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01588418) (`ctg-observation-nct01588418-2017-11-24-0063b9663288`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01588418." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01588418-exenatide-v1 SHA-256: 740ef9481259738213d2db2f5541ee66f92b2ae7bd7b74e632b76565dab9914c.

---

<a id="clinicaltrials-gov-nct01590433-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01590433

> PeptideScanner retained ClinicalTrials.gov record NCT01590433 at 2026-07-30T20:02:09.394Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01590433-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01590433-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01590433-exenatide-v1
- Content SHA-256: `c37aed45550c8ce5ed700ab22acfe16df34dd27a633767146691705ccf3a442f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01590433 ([`ctg-observation-nct01590433-2021-06-23-0f07b9d96441`](#source-ctg-observation-nct01590433-2021-06-23-0f07b9d96441))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01590433 at 2026-07-30T20:02:09.394Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01590433-2021-06-23-0f07b9d96441`](#source-ctg-observation-nct01590433-2021-06-23-0f07b9d96441))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01590433 at 2026-07-30T20:02:09.394Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01590433-2021-06-23-0f07b9d96441`](#source-ctg-observation-nct01590433-2021-06-23-0f07b9d96441))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01590433-2021-06-23-0f07b9d96441`](#source-ctg-observation-nct01590433-2021-06-23-0f07b9d96441))

### Sources

<a id="source-ctg-observation-nct01590433-2021-06-23-0f07b9d96441"></a>
- **ClinicalTrials.gov record NCT01590433 · retained source version 2021-06-23:0f07b9d964414f44f21599dbc5b69ed06525b3a6efd1770838a1e113dc609174** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01590433) (`ctg-observation-nct01590433-2021-06-23-0f07b9d96441`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01590433." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01590433-exenatide-v1 SHA-256: c37aed45550c8ce5ed700ab22acfe16df34dd27a633767146691705ccf3a442f.

---

<a id="clinicaltrials-gov-nct01951651-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01951651

> PeptideScanner retained ClinicalTrials.gov record NCT01951651 at 2026-07-30T21:37:20.824Z. Its registry update date was 2016-05-16, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01951651-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-05-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01951651-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01951651-exenatide-v1
- Content SHA-256: `6d3ff25da61d3583eec7c3b43661a9cb1d44a9297fee8838a7fc8a4a2a603e89`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01951651 ([`ctg-observation-nct01951651-2016-05-16-7714ac7cac3c`](#source-ctg-observation-nct01951651-2016-05-16-7714ac7cac3c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01951651 at 2026-07-30T21:37:20.824Z. Its registry update date was 2016-05-16, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01951651-2016-05-16-7714ac7cac3c`](#source-ctg-observation-nct01951651-2016-05-16-7714ac7cac3c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01951651 at 2026-07-30T21:37:20.824Z. Its registry update date was 2016-05-16, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01951651-2016-05-16-7714ac7cac3c`](#source-ctg-observation-nct01951651-2016-05-16-7714ac7cac3c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01951651-2016-05-16-7714ac7cac3c`](#source-ctg-observation-nct01951651-2016-05-16-7714ac7cac3c))

### Sources

<a id="source-ctg-observation-nct01951651-2016-05-16-7714ac7cac3c"></a>
- **ClinicalTrials.gov record NCT01951651 · retained source version 2016-05-16:7714ac7cac3cdd9de5955464f9fd0c2df4143272304bb67cf17c318ce33a0048** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01951651) (`ctg-observation-nct01951651-2016-05-16-7714ac7cac3c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01951651." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01951651-exenatide-v1 SHA-256: 6d3ff25da61d3583eec7c3b43661a9cb1d44a9297fee8838a7fc8a4a2a603e89.

---

<a id="clinicaltrials-gov-nct01969149-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01969149

> PeptideScanner retained ClinicalTrials.gov record NCT01969149 at 2026-07-30T21:22:00.262Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01969149-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01969149-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01969149-exenatide-v1
- Content SHA-256: `55e3c4b5db2f7cd1cae810269001e60c4ac87cbddc42772554ef1882c5032fa7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01969149 ([`ctg-observation-nct01969149-2017-10-06-401d38d4b987`](#source-ctg-observation-nct01969149-2017-10-06-401d38d4b987))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01969149 at 2026-07-30T21:22:00.262Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01969149-2017-10-06-401d38d4b987`](#source-ctg-observation-nct01969149-2017-10-06-401d38d4b987))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01969149 at 2026-07-30T21:22:00.262Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01969149-2017-10-06-401d38d4b987`](#source-ctg-observation-nct01969149-2017-10-06-401d38d4b987))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01969149-2017-10-06-401d38d4b987`](#source-ctg-observation-nct01969149-2017-10-06-401d38d4b987))

### Sources

<a id="source-ctg-observation-nct01969149-2017-10-06-401d38d4b987"></a>
- **ClinicalTrials.gov record NCT01969149 · retained source version 2017-10-06:401d38d4b987cd5e44943d3736165482142bc2b9410b35d912baaedc47e24e08** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01969149) (`ctg-observation-nct01969149-2017-10-06-401d38d4b987`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01969149." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01969149-exenatide-v1 SHA-256: 55e3c4b5db2f7cd1cae810269001e60c4ac87cbddc42772554ef1882c5032fa7.

---

<a id="clinicaltrials-gov-nct01971242-exenatide-v1"></a>

## ClinicalTrials.gov record NCT01971242

> PeptideScanner retained ClinicalTrials.gov record NCT01971242 at 2026-07-30T21:34:56.502Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct01971242-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-11-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01971242-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01971242-exenatide-v1
- Content SHA-256: `b4595ee87e40888e40745cb67c1f4b84fdf694e2acaa7c2ac3b5d2982ac774f9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01971242 ([`ctg-observation-nct01971242-2016-11-17-4d4f08b2f251`](#source-ctg-observation-nct01971242-2016-11-17-4d4f08b2f251))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01971242 at 2026-07-30T21:34:56.502Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01971242-2016-11-17-4d4f08b2f251`](#source-ctg-observation-nct01971242-2016-11-17-4d4f08b2f251))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01971242 at 2026-07-30T21:34:56.502Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct01971242-2016-11-17-4d4f08b2f251`](#source-ctg-observation-nct01971242-2016-11-17-4d4f08b2f251))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01971242-2016-11-17-4d4f08b2f251`](#source-ctg-observation-nct01971242-2016-11-17-4d4f08b2f251))

### Sources

<a id="source-ctg-observation-nct01971242-2016-11-17-4d4f08b2f251"></a>
- **ClinicalTrials.gov record NCT01971242 · retained source version 2016-11-17:4d4f08b2f25187bf6e1fd73fd678c846a840551049bfceaf3fef874766a1f262** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01971242) (`ctg-observation-nct01971242-2016-11-17-4d4f08b2f251`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01971242." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct01971242-exenatide-v1 SHA-256: b4595ee87e40888e40745cb67c1f4b84fdf694e2acaa7c2ac3b5d2982ac774f9.

---

<a id="clinicaltrials-gov-nct02092597-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02092597

> PeptideScanner retained ClinicalTrials.gov record NCT02092597 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-02-07, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02092597-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02092597-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02092597-exenatide-v1
- Content SHA-256: `1cfda599fde6512d5facac4e66687d3c7e8ee2cf0a5c7315d2677a8fd1789ddd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02092597 ([`ctg-observation-nct02092597-2018-02-07-29fd3c56a200`](#source-ctg-observation-nct02092597-2018-02-07-29fd3c56a200))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02092597 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-02-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02092597-2018-02-07-29fd3c56a200`](#source-ctg-observation-nct02092597-2018-02-07-29fd3c56a200))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02092597 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-02-07, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02092597-2018-02-07-29fd3c56a200`](#source-ctg-observation-nct02092597-2018-02-07-29fd3c56a200))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02092597-2018-02-07-29fd3c56a200`](#source-ctg-observation-nct02092597-2018-02-07-29fd3c56a200))

### Sources

<a id="source-ctg-observation-nct02092597-2018-02-07-29fd3c56a200"></a>
- **ClinicalTrials.gov record NCT02092597 · retained source version 2018-02-07:29fd3c56a200129735d0b1c5f6418907fe0d937c452aec4613d6fa9f16badd25** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02092597) (`ctg-observation-nct02092597-2018-02-07-29fd3c56a200`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02092597." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02092597-exenatide-v1 SHA-256: 1cfda599fde6512d5facac4e66687d3c7e8ee2cf0a5c7315d2677a8fd1789ddd.

---

<a id="clinicaltrials-gov-nct02104739-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02104739

> PeptideScanner retained ClinicalTrials.gov record NCT02104739 at 2026-07-30T21:10:03.007Z. Its registry update date was 2018-07-03, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02104739-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-07-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02104739-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02104739-exenatide-v1
- Content SHA-256: `21d31f9dea8a77c3f9603e20b35ecf7cb6346e5019c034ed4e9568f65b09672d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02104739 ([`ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c`](#source-ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02104739 at 2026-07-30T21:10:03.007Z. Its registry update date was 2018-07-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c`](#source-ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02104739 at 2026-07-30T21:10:03.007Z. Its registry update date was 2018-07-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c`](#source-ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c`](#source-ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c))

### Sources

<a id="source-ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c"></a>
- **ClinicalTrials.gov record NCT02104739 · retained source version 2018-07-03:9a1d7e51cd6cca9e6d3bb3cdfccc6bb3d2a61c0b9538fb9da669d8728d3da424** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02104739) (`ctg-observation-nct02104739-2018-07-03-9a1d7e51cd6c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02104739." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02104739-exenatide-v1 SHA-256: 21d31f9dea8a77c3f9603e20b35ecf7cb6346e5019c034ed4e9568f65b09672d.

---

<a id="clinicaltrials-gov-nct02157974-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02157974

> PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02157974-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02157974-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02157974-exenatide-v1
- Content SHA-256: `492211acbd88d2571cef9bcaa25fa627a238a0c9947fd4061b7023b754a75df1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02157974 ([`ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5`](#source-ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5`](#source-ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5`](#source-ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5`](#source-ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5))

### Sources

<a id="source-ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5"></a>
- **ClinicalTrials.gov record NCT02157974 · retained source version 2024-06-04:192bb9d1aaf5d4faadc91b8c8f8c70c25e78419ac8286f0bbc83959cd9fe4ac1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02157974) (`ctg-observation-nct02157974-2024-06-04-192bb9d1aaf5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02157974." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02157974-exenatide-v1 SHA-256: 492211acbd88d2571cef9bcaa25fa627a238a0c9947fd4061b7023b754a75df1.

---

<a id="clinicaltrials-gov-nct02160990-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02160990

> PeptideScanner retained ClinicalTrials.gov record NCT02160990 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02160990-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02160990-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02160990-exenatide-v1
- Content SHA-256: `9ad18a0940b0cce48f75cae650ac53d9649603528f74404087b04c7fd07d6822`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02160990 ([`ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f`](#source-ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02160990 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f`](#source-ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02160990 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f`](#source-ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f`](#source-ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f))

### Sources

<a id="source-ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f"></a>
- **ClinicalTrials.gov record NCT02160990 · retained source version 2016-08-09:fc0ca1127b0fc9491db264712456c0f1de15754ce1d1f99f462131a813fe3b48** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02160990) (`ctg-observation-nct02160990-2016-08-09-fc0ca1127b0f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02160990." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02160990-exenatide-v1 SHA-256: 9ad18a0940b0cce48f75cae650ac53d9649603528f74404087b04c7fd07d6822.

---

<a id="clinicaltrials-gov-nct02313220-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02313220

> PeptideScanner retained ClinicalTrials.gov record NCT02313220 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02313220-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-11-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02313220-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02313220-exenatide-v1
- Content SHA-256: `ae135ee114a22305f6176888735961e7898b4064c8a342df840a5edc8a54e7e1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02313220 ([`ctg-observation-nct02313220-2016-11-17-daed41852649`](#source-ctg-observation-nct02313220-2016-11-17-daed41852649))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02313220 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02313220-2016-11-17-daed41852649`](#source-ctg-observation-nct02313220-2016-11-17-daed41852649))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02313220 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02313220-2016-11-17-daed41852649`](#source-ctg-observation-nct02313220-2016-11-17-daed41852649))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02313220-2016-11-17-daed41852649`](#source-ctg-observation-nct02313220-2016-11-17-daed41852649))

### Sources

<a id="source-ctg-observation-nct02313220-2016-11-17-daed41852649"></a>
- **ClinicalTrials.gov record NCT02313220 · retained source version 2016-11-17:daed418526494a31080a3f8cc8876646c815094626ca1c4722be3ff01987b0e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02313220) (`ctg-observation-nct02313220-2016-11-17-daed41852649`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02313220." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02313220-exenatide-v1 SHA-256: ae135ee114a22305f6176888735961e7898b4064c8a342df840a5edc8a54e7e1.

---

<a id="clinicaltrials-gov-nct02325960-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02325960

> PeptideScanner retained ClinicalTrials.gov record NCT02325960 at 2026-07-30T21:25:37.027Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02325960-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02325960-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02325960-exenatide-v1
- Content SHA-256: `647ca9989b7a0563ffff5b0383ccd2857be0c810ca317f9e61e60e1c9a176f03`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02325960 ([`ctg-observation-nct02325960-2017-02-23-9b383a833507`](#source-ctg-observation-nct02325960-2017-02-23-9b383a833507))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02325960 at 2026-07-30T21:25:37.027Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02325960-2017-02-23-9b383a833507`](#source-ctg-observation-nct02325960-2017-02-23-9b383a833507))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02325960 at 2026-07-30T21:25:37.027Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02325960-2017-02-23-9b383a833507`](#source-ctg-observation-nct02325960-2017-02-23-9b383a833507))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02325960-2017-02-23-9b383a833507`](#source-ctg-observation-nct02325960-2017-02-23-9b383a833507))

### Sources

<a id="source-ctg-observation-nct02325960-2017-02-23-9b383a833507"></a>
- **ClinicalTrials.gov record NCT02325960 · retained source version 2017-02-23:9b383a833507172e38714b3341228a564a3610e80befc7700fd82cb253955665** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02325960) (`ctg-observation-nct02325960-2017-02-23-9b383a833507`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02325960." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02325960-exenatide-v1 SHA-256: 647ca9989b7a0563ffff5b0383ccd2857be0c810ca317f9e61e60e1c9a176f03.

---

<a id="clinicaltrials-gov-nct02404376-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02404376

> PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02404376-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-11-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02404376-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02404376-exenatide-v1
- Content SHA-256: `7a6d8e245e0f7c9c9c7fa8782fcec020bde870650d4d8999d5cd1694db4b7766`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02404376 ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

### Sources

<a id="source-ctg-observation-nct02404376-2020-11-03-be534246b18f"></a>
- **ClinicalTrials.gov record NCT02404376 · retained source version 2020-11-03:be534246b18f61d95606ad83c659b346c82744e02b1672de711e542d1ffcae41** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02404376) (`ctg-observation-nct02404376-2020-11-03-be534246b18f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02404376." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02404376-exenatide-v1 SHA-256: 7a6d8e245e0f7c9c9c7fa8782fcec020bde870650d4d8999d5cd1694db4b7766.

---

<a id="clinicaltrials-gov-nct02664441-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02664441

> PeptideScanner retained ClinicalTrials.gov record NCT02664441 at 2026-07-30T19:39:59.673Z. Its registry update date was 2022-05-05, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02664441-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02664441-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02664441-exenatide-v1
- Content SHA-256: `8e511978b30f5f0aa96bfda1fd3aa34daa9e29ef077275d9596a81b243383918`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02664441 ([`ctg-observation-nct02664441-2022-05-05-337486c8234c`](#source-ctg-observation-nct02664441-2022-05-05-337486c8234c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02664441 at 2026-07-30T19:39:59.673Z. Its registry update date was 2022-05-05, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02664441-2022-05-05-337486c8234c`](#source-ctg-observation-nct02664441-2022-05-05-337486c8234c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02664441 at 2026-07-30T19:39:59.673Z. Its registry update date was 2022-05-05, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02664441-2022-05-05-337486c8234c`](#source-ctg-observation-nct02664441-2022-05-05-337486c8234c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02664441-2022-05-05-337486c8234c`](#source-ctg-observation-nct02664441-2022-05-05-337486c8234c))

### Sources

<a id="source-ctg-observation-nct02664441-2022-05-05-337486c8234c"></a>
- **ClinicalTrials.gov record NCT02664441 · retained source version 2022-05-05:337486c8234cc36aae4825d5ca0b8f0f64de5801d09f3072a3cd28dd420e6975** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02664441) (`ctg-observation-nct02664441-2022-05-05-337486c8234c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02664441." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02664441-exenatide-v1 SHA-256: 8e511978b30f5f0aa96bfda1fd3aa34daa9e29ef077275d9596a81b243383918.

---

<a id="clinicaltrials-gov-nct02685852-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02685852

> PeptideScanner retained ClinicalTrials.gov record NCT02685852 at 2026-07-30T20:03:05.483Z. Its registry update date was 2021-05-06, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02685852-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02685852-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02685852-exenatide-v1
- Content SHA-256: `64706bd8fc47b9ef1a6190ea045be3a514f07e210c83a14b70700200c9dd626e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02685852 ([`ctg-observation-nct02685852-2021-05-06-db13d17dee89`](#source-ctg-observation-nct02685852-2021-05-06-db13d17dee89))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02685852 at 2026-07-30T20:03:05.483Z. Its registry update date was 2021-05-06, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02685852-2021-05-06-db13d17dee89`](#source-ctg-observation-nct02685852-2021-05-06-db13d17dee89))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02685852 at 2026-07-30T20:03:05.483Z. Its registry update date was 2021-05-06, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02685852-2021-05-06-db13d17dee89`](#source-ctg-observation-nct02685852-2021-05-06-db13d17dee89))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02685852-2021-05-06-db13d17dee89`](#source-ctg-observation-nct02685852-2021-05-06-db13d17dee89))

### Sources

<a id="source-ctg-observation-nct02685852-2021-05-06-db13d17dee89"></a>
- **ClinicalTrials.gov record NCT02685852 · retained source version 2021-05-06:db13d17dee8905cf7f94421a8c4d1fea9e7783eb7afbba96a27b3de2ffbe4b8a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02685852) (`ctg-observation-nct02685852-2021-05-06-db13d17dee89`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02685852." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02685852-exenatide-v1 SHA-256: 64706bd8fc47b9ef1a6190ea045be3a514f07e210c83a14b70700200c9dd626e.

---

<a id="clinicaltrials-gov-nct02860923-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02860923

> PeptideScanner retained ClinicalTrials.gov record NCT02860923 at 2026-07-30T16:19:36.924Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02860923-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02860923-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02860923-exenatide-v1
- Content SHA-256: `98a65fe7eb0d1914de19c4e06700a2e83bf40e446c28cc90846ef271dcf8600e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02860923 ([`ctg-observation-nct02860923-2026-05-22-36d96a383758`](#source-ctg-observation-nct02860923-2026-05-22-36d96a383758))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02860923 at 2026-07-30T16:19:36.924Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02860923-2026-05-22-36d96a383758`](#source-ctg-observation-nct02860923-2026-05-22-36d96a383758))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02860923 at 2026-07-30T16:19:36.924Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02860923-2026-05-22-36d96a383758`](#source-ctg-observation-nct02860923-2026-05-22-36d96a383758))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02860923-2026-05-22-36d96a383758`](#source-ctg-observation-nct02860923-2026-05-22-36d96a383758))

### Sources

<a id="source-ctg-observation-nct02860923-2026-05-22-36d96a383758"></a>
- **ClinicalTrials.gov record NCT02860923 · retained source version 2026-05-22:36d96a3837587e56a762a744e3c3a5cd1ad36b439a9e273a0797e43a25d83aff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02860923) (`ctg-observation-nct02860923-2026-05-22-36d96a383758`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02860923." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02860923-exenatide-v1 SHA-256: 98a65fe7eb0d1914de19c4e06700a2e83bf40e446c28cc90846ef271dcf8600e.

---

<a id="clinicaltrials-gov-nct02981069-exenatide-v1"></a>

## ClinicalTrials.gov record NCT02981069

> PeptideScanner retained ClinicalTrials.gov record NCT02981069 at 2026-07-30T19:10:42.759Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02981069-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02981069-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02981069-exenatide-v1
- Content SHA-256: `b51b49a0c8a6165fc8f5a9e74d1ff562db892b93e7909b656a197045ba01d15d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02981069 ([`ctg-observation-nct02981069-2023-07-20-b3befdbf6979`](#source-ctg-observation-nct02981069-2023-07-20-b3befdbf6979))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02981069 at 2026-07-30T19:10:42.759Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02981069-2023-07-20-b3befdbf6979`](#source-ctg-observation-nct02981069-2023-07-20-b3befdbf6979))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02981069 at 2026-07-30T19:10:42.759Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02981069-2023-07-20-b3befdbf6979`](#source-ctg-observation-nct02981069-2023-07-20-b3befdbf6979))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02981069-2023-07-20-b3befdbf6979`](#source-ctg-observation-nct02981069-2023-07-20-b3befdbf6979))

### Sources

<a id="source-ctg-observation-nct02981069-2023-07-20-b3befdbf6979"></a>
- **ClinicalTrials.gov record NCT02981069 · retained source version 2023-07-20:b3befdbf6979c4b5878eb1f2026e9657923457a72f843d18552c88f4c9557cde** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02981069) (`ctg-observation-nct02981069-2023-07-20-b3befdbf6979`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02981069." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct02981069-exenatide-v1 SHA-256: b51b49a0c8a6165fc8f5a9e74d1ff562db892b93e7909b656a197045ba01d15d.

---

<a id="clinicaltrials-gov-nct03331289-exenatide-v1"></a>

## ClinicalTrials.gov record NCT03331289

> PeptideScanner retained ClinicalTrials.gov record NCT03331289 at 2026-07-30T19:10:42.713Z. Its registry update date was 2023-07-24, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct03331289-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03331289-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct03331289-exenatide-v1
- Content SHA-256: `07c27c75f76d76e7f3210841a988819299c1c7a26e68320e491f7f370a14ad61`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03331289 ([`ctg-observation-nct03331289-2023-07-24-7f36477f9fdc`](#source-ctg-observation-nct03331289-2023-07-24-7f36477f9fdc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03331289 at 2026-07-30T19:10:42.713Z. Its registry update date was 2023-07-24, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03331289-2023-07-24-7f36477f9fdc`](#source-ctg-observation-nct03331289-2023-07-24-7f36477f9fdc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03331289 at 2026-07-30T19:10:42.713Z. Its registry update date was 2023-07-24, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03331289-2023-07-24-7f36477f9fdc`](#source-ctg-observation-nct03331289-2023-07-24-7f36477f9fdc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03331289-2023-07-24-7f36477f9fdc`](#source-ctg-observation-nct03331289-2023-07-24-7f36477f9fdc))

### Sources

<a id="source-ctg-observation-nct03331289-2023-07-24-7f36477f9fdc"></a>
- **ClinicalTrials.gov record NCT03331289 · retained source version 2023-07-24:7f36477f9fdc68d8b37d4237ff709c4f3493a25801c94fe7e7679d602b714b27** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03331289) (`ctg-observation-nct03331289-2023-07-24-7f36477f9fdc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03331289." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct03331289-exenatide-v1 SHA-256: 07c27c75f76d76e7f3210841a988819299c1c7a26e68320e491f7f370a14ad61.

---

<a id="clinicaltrials-gov-nct03352869-exenatide-v1"></a>

## ClinicalTrials.gov record NCT03352869

> PeptideScanner retained ClinicalTrials.gov record NCT03352869 at 2026-07-30T20:45:58.274Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct03352869-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03352869-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct03352869-exenatide-v1
- Content SHA-256: `b01b646e5d624bed3e9b8cea0f00c0d53b395076e5aee1472de81ec894be7ba9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03352869 ([`ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2`](#source-ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03352869 at 2026-07-30T20:45:58.274Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2`](#source-ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03352869 at 2026-07-30T20:45:58.274Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2`](#source-ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2`](#source-ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2))

### Sources

<a id="source-ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2"></a>
- **ClinicalTrials.gov record NCT03352869 · retained source version 2019-09-11:5dff8ce2e7b21e99b14661e8d246e146a446893a44152e8fbf806fa04dbe6cbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03352869) (`ctg-observation-nct03352869-2019-09-11-5dff8ce2e7b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03352869." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct03352869-exenatide-v1 SHA-256: b01b646e5d624bed3e9b8cea0f00c0d53b395076e5aee1472de81ec894be7ba9.

---

<a id="clinicaltrials-gov-nct03456687-exenatide-v1"></a>

## ClinicalTrials.gov record NCT03456687

> PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct03456687-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03456687-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct03456687-exenatide-v1
- Content SHA-256: `9453e5f6739b7e99d9b1de24a6e0f1460cbe0d29fc08d608f1fe20ec0740ab1b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03456687 ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

### Sources

<a id="source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb"></a>
- **ClinicalTrials.gov record NCT03456687 · retained source version 2022-09-16:596d8102a1cb6014bd8929e5f65d9b310664ed67702ed776130faee35a133f68** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03456687) (`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03456687." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct03456687-exenatide-v1 SHA-256: 9453e5f6739b7e99d9b1de24a6e0f1460cbe0d29fc08d608f1fe20ec0740ab1b.

---

<a id="clinicaltrials-gov-nct04303819-exenatide-v1"></a>

## ClinicalTrials.gov record NCT04303819

> PeptideScanner retained ClinicalTrials.gov record NCT04303819 at 2026-07-30T20:26:41.665Z. Its registry update date was 2020-06-11, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct04303819-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-06-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04303819-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct04303819-exenatide-v1
- Content SHA-256: `c13a04005490ef96a640fe9874fb7a92983fa3bc3f2731cd68ba0fbc37e019e3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04303819 ([`ctg-observation-nct04303819-2020-06-11-46df8e80e5e6`](#source-ctg-observation-nct04303819-2020-06-11-46df8e80e5e6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04303819 at 2026-07-30T20:26:41.665Z. Its registry update date was 2020-06-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct04303819-2020-06-11-46df8e80e5e6`](#source-ctg-observation-nct04303819-2020-06-11-46df8e80e5e6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04303819 at 2026-07-30T20:26:41.665Z. Its registry update date was 2020-06-11, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct04303819-2020-06-11-46df8e80e5e6`](#source-ctg-observation-nct04303819-2020-06-11-46df8e80e5e6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04303819-2020-06-11-46df8e80e5e6`](#source-ctg-observation-nct04303819-2020-06-11-46df8e80e5e6))

### Sources

<a id="source-ctg-observation-nct04303819-2020-06-11-46df8e80e5e6"></a>
- **ClinicalTrials.gov record NCT04303819 · retained source version 2020-06-11:46df8e80e5e64b512c4ffd93685c8f58cd10de6927d06973822d1f53e97afea6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04303819) (`ctg-observation-nct04303819-2020-06-11-46df8e80e5e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04303819." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct04303819-exenatide-v1 SHA-256: c13a04005490ef96a640fe9874fb7a92983fa3bc3f2731cd68ba0fbc37e019e3.

---

<a id="clinicaltrials-gov-nct04909333-exenatide-v1"></a>

## ClinicalTrials.gov record NCT04909333

> PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct04909333-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-05-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04909333-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct04909333-exenatide-v1
- Content SHA-256: `5420ef4d0933d102c9556a11f8bab29acac943f86c83b922f577975ff46c491d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04909333 ([`ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa`](#source-ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa`](#source-ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa`](#source-ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa`](#source-ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa))

### Sources

<a id="source-ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa"></a>
- **ClinicalTrials.gov record NCT04909333 · retained source version 2024-05-08:f6f455f5dbaa64c82f049336bdbaa221dad5cf89c72068def732d8ad854b7ec0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04909333) (`ctg-observation-nct04909333-2024-05-08-f6f455f5dbaa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04909333." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct04909333-exenatide-v1 SHA-256: 5420ef4d0933d102c9556a11f8bab29acac943f86c83b922f577975ff46c491d.

---

<a id="clinicaltrials-gov-nct05482789-exenatide-v1"></a>

## ClinicalTrials.gov record NCT05482789

> PeptideScanner retained ClinicalTrials.gov record NCT05482789 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct05482789-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05482789-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct05482789-exenatide-v1
- Content SHA-256: `ede74f7daf88f668284c14d0126f47cebfd77adb50a19408ec9f57c4e323aeed`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05482789 ([`ctg-observation-nct05482789-2026-04-20-9822addd6fd8`](#source-ctg-observation-nct05482789-2026-04-20-9822addd6fd8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05482789 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct05482789-2026-04-20-9822addd6fd8`](#source-ctg-observation-nct05482789-2026-04-20-9822addd6fd8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05482789 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct05482789-2026-04-20-9822addd6fd8`](#source-ctg-observation-nct05482789-2026-04-20-9822addd6fd8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05482789-2026-04-20-9822addd6fd8`](#source-ctg-observation-nct05482789-2026-04-20-9822addd6fd8))

### Sources

<a id="source-ctg-observation-nct05482789-2026-04-20-9822addd6fd8"></a>
- **ClinicalTrials.gov record NCT05482789 · retained source version 2026-04-20:9822addd6fd8fcdf96ef1d067b9aff5e4b8f8b125187e92449b2cd0a5157c91d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05482789) (`ctg-observation-nct05482789-2026-04-20-9822addd6fd8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05482789." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct05482789-exenatide-v1 SHA-256: ede74f7daf88f668284c14d0126f47cebfd77adb50a19408ec9f57c4e323aeed.

---

<a id="clinicaltrials-gov-nct05663515-exenatide-v1"></a>

## ClinicalTrials.gov record NCT05663515

> PeptideScanner retained ClinicalTrials.gov record NCT05663515 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct05663515-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-04
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05663515-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct05663515-exenatide-v1
- Content SHA-256: `8f6e418e8feff67790ce0cd0b2ad7d2c0d4124ae7871ee41f46ce0d51f04fc86`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05663515 ([`ctg-observation-nct05663515-2026-08-04-c1bd074f72a5`](#source-ctg-observation-nct05663515-2026-08-04-c1bd074f72a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05663515 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct05663515-2026-08-04-c1bd074f72a5`](#source-ctg-observation-nct05663515-2026-08-04-c1bd074f72a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05663515 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct05663515-2026-08-04-c1bd074f72a5`](#source-ctg-observation-nct05663515-2026-08-04-c1bd074f72a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05663515-2026-08-04-c1bd074f72a5`](#source-ctg-observation-nct05663515-2026-08-04-c1bd074f72a5))

### Sources

<a id="source-ctg-observation-nct05663515-2026-08-04-c1bd074f72a5"></a>
- **ClinicalTrials.gov record NCT05663515 · retained source version 2026-08-04:c1bd074f72a5d779597ace59cb9f39678d1183bb902c2a8081822a2a21190388** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05663515) (`ctg-observation-nct05663515-2026-08-04-c1bd074f72a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05663515." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#clinicaltrials-gov-nct05663515-exenatide-v1 SHA-256: 8f6e418e8feff67790ce0cd0b2ad7d2c0d4124ae7871ee41f46ce0d51f04fc86.

---

<a id="dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-v1"></a>

## Exenatide DailyMed SPL version 11

> DailyMed lists Structured Product Labeling version 11 for the reviewed Exenatide label family with a published date of 2024-11-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-25
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-v1
- Content SHA-256: `e283e0148f7b311e9f6b6b8a3a3cea2fcadafa4051ace0cb689564632d38d09b`

### Claims and source pins

#### Headline

Exenatide DailyMed SPL version 11 ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history))

#### Summary

DailyMed lists Structured Product Labeling version 11 for the reviewed Exenatide label family with a published date of 2024-11-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 11 for the reviewed Exenatide label family with a published date of 2024-11-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history))

### Sources

<a id="source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history"></a>
- **DailyMed SPL SET ID e6cb5c8f-e97f-4a6a-95a4-939fd2393949 · SPL version 11 · published 2024-11-25 · retained ZIP SHA-256 65b5ffdc263016f6b9e301f808b23d049a3c3f2dbd4e49030c2cf04b18af08fd** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=11) (`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide DailyMed SPL version 11." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v11-v1 SHA-256: e283e0148f7b311e9f6b6b8a3a3cea2fcadafa4051ace0cb689564632d38d09b.

---

<a id="dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-v1"></a>

## Exenatide DailyMed SPL version 12

> DailyMed lists Structured Product Labeling version 12 for the reviewed Exenatide label family with a published date of 2025-08-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-v1
- Content SHA-256: `f8f4123ceba3558c640ef5bcbb796321fe5fb14852bd693b93a1886f771bc97e`

### Claims and source pins

#### Headline

Exenatide DailyMed SPL version 12 ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history))

#### Summary

DailyMed lists Structured Product Labeling version 12 for the reviewed Exenatide label family with a published date of 2025-08-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 12 for the reviewed Exenatide label family with a published date of 2025-08-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history))

### Sources

<a id="source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history"></a>
- **DailyMed SPL SET ID e6cb5c8f-e97f-4a6a-95a4-939fd2393949 · SPL version 12 · published 2025-08-07 · retained ZIP SHA-256 bf1b181a33305d1cc245e8e501e7199c559c2526e4652ded61c45903d69f813b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=12) (`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide DailyMed SPL version 12." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v12-v1 SHA-256: f8f4123ceba3558c640ef5bcbb796321fe5fb14852bd693b93a1886f771bc97e.

---

<a id="dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-v1"></a>

## Exenatide DailyMed SPL version 13

> DailyMed lists Structured Product Labeling version 13 for the reviewed Exenatide label family with a published date of 2025-08-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-13
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-v1
- Content SHA-256: `aa708566f209c7fdb2a22189dad807eeddd2e7cf06cedcb97b4785a66df5bd08`

### Claims and source pins

#### Headline

Exenatide DailyMed SPL version 13 ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history))

#### Summary

DailyMed lists Structured Product Labeling version 13 for the reviewed Exenatide label family with a published date of 2025-08-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 13 for the reviewed Exenatide label family with a published date of 2025-08-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history))

### Sources

<a id="source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history"></a>
- **DailyMed SPL SET ID e6cb5c8f-e97f-4a6a-95a4-939fd2393949 · SPL version 13 · published 2025-08-13 · retained ZIP SHA-256 2e382ab2039e986b59f43bfcde763602a73fa36b2e31bf95cd28215c68ac89a9** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=13) (`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide DailyMed SPL version 13." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v13-v1 SHA-256: aa708566f209c7fdb2a22189dad807eeddd2e7cf06cedcb97b4785a66df5bd08.

---

<a id="dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-v1"></a>

## Exenatide DailyMed SPL version 16

> DailyMed lists Structured Product Labeling version 16 for the reviewed Exenatide label family with a published date of 2026-01-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16:v1`
- Evidence domain: Regulatory
- Date in source: 2026-01-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-v1
- Content SHA-256: `41b56e7d5e433b689374f9b3730bb3117bab5016a69e682c865bd8d45d89a963`

### Claims and source pins

#### Headline

Exenatide DailyMed SPL version 16 ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history))

#### Summary

DailyMed lists Structured Product Labeling version 16 for the reviewed Exenatide label family with a published date of 2026-01-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 16 for the reviewed Exenatide label family with a published date of 2026-01-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history))

### Sources

<a id="source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history"></a>
- **DailyMed SPL SET ID e6cb5c8f-e97f-4a6a-95a4-939fd2393949 · SPL version 16 · published 2026-01-12 · retained ZIP SHA-256 d3e0adf04135f6aabab885b63fa16d4ee519b39ed35eaa39d2131bf59062cd7b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=16) (`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide DailyMed SPL version 16." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v16-v1 SHA-256: 41b56e7d5e433b689374f9b3730bb3117bab5016a69e682c865bd8d45d89a963.

---

<a id="dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-v1"></a>

## Exenatide DailyMed SPL version 17

> DailyMed lists Structured Product Labeling version 17 for the reviewed Exenatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17:v1`
- Evidence domain: Regulatory
- Date in source: 2026-06-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-v1
- Content SHA-256: `cd0eda951adc86b91f64f7f5f5458f24fe8dd40abdcb60e430f8b3d0d0a1a607`

### Claims and source pins

#### Headline

Exenatide DailyMed SPL version 17 ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history))

#### Summary

DailyMed lists Structured Product Labeling version 17 for the reviewed Exenatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 17 for the reviewed Exenatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history`](#source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history))

### Sources

<a id="source-dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history"></a>
- **DailyMed SPL SET ID e6cb5c8f-e97f-4a6a-95a4-939fd2393949 · SPL version 17 · published 2026-06-30 · retained ZIP SHA-256 3a938f95f72fa59782922c490dc415fef7aa62df9872a1da096e4bff95b65abb** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=17) (`dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide DailyMed SPL version 17." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#dailymed-label-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17-v1 SHA-256: cd0eda951adc86b91f64f7f5f5458f24fe8dd40abdcb60e430f8b3d0d0a1a607.

---

<a id="fda-drugs-anda206697-v1"></a>

## Drugs@FDA application ANDA206697

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206697 with status AP dated 2024-11-19, and names exenatide synthetic among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206697:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-19
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206697/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-anda206697-v1
- Content SHA-256: `ec7fd983c2c2dca0db17ddc24d06fe425a3fba163e7920f9a12df3bfdf656fab`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206697 ([`fda-drugs-anda206697-2024-11-19-5725057d6a94`](#source-fda-drugs-anda206697-2024-11-19-5725057d6a94))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206697 with status AP dated 2024-11-19, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-anda206697-2024-11-19-5725057d6a94`](#source-fda-drugs-anda206697-2024-11-19-5725057d6a94))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206697 with status AP dated 2024-11-19, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-anda206697-2024-11-19-5725057d6a94`](#source-fda-drugs-anda206697-2024-11-19-5725057d6a94))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206697-2024-11-19-5725057d6a94`](#source-fda-drugs-anda206697-2024-11-19-5725057d6a94))

### Sources

<a id="source-fda-drugs-anda206697-2024-11-19-5725057d6a94"></a>
- **Drugs@FDA application ANDA206697 · original submission status AP · 2024-11-19 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206697%22&limit=1) (`fda-drugs-anda206697-2024-11-19-5725057d6a94`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206697." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-anda206697-v1 SHA-256: ec7fd983c2c2dca0db17ddc24d06fe425a3fba163e7920f9a12df3bfdf656fab.

---

<a id="fda-drugs-nda021773-v1"></a>

## Drugs@FDA application NDA021773

> The official Drugs@FDA dataset lists original submission 1 for NDA 021773 with status AP dated 2005-04-28, and names exenatide synthetic among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021773:v1`
- Evidence domain: Regulatory
- Date in source: 2005-04-28
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021773/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda021773-v1
- Content SHA-256: `ea63344d718511f38820cc38397db28e653c733dab318b78ab9ddb1561f39b7e`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021773 ([`fda-drugs-nda021773-2005-04-28-80405b2e0c23`](#source-fda-drugs-nda021773-2005-04-28-80405b2e0c23))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021773 with status AP dated 2005-04-28, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda021773-2005-04-28-80405b2e0c23`](#source-fda-drugs-nda021773-2005-04-28-80405b2e0c23))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021773 with status AP dated 2005-04-28, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda021773-2005-04-28-80405b2e0c23`](#source-fda-drugs-nda021773-2005-04-28-80405b2e0c23))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021773-2005-04-28-80405b2e0c23`](#source-fda-drugs-nda021773-2005-04-28-80405b2e0c23))

### Sources

<a id="source-fda-drugs-nda021773-2005-04-28-80405b2e0c23"></a>
- **Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021773%22&limit=1) (`fda-drugs-nda021773-2005-04-28-80405b2e0c23`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021773." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda021773-v1 SHA-256: ea63344d718511f38820cc38397db28e653c733dab318b78ab9ddb1561f39b7e.

---

<a id="fda-drugs-nda021919-v1"></a>

## Drugs@FDA application NDA021919

> The official Drugs@FDA dataset lists original submission 1 for NDA 021919 with status AP dated 2009-10-30, and names exenatide synthetic among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021919:v1`
- Evidence domain: Regulatory
- Date in source: 2009-10-30
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021919/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda021919-v1
- Content SHA-256: `fbfc78fee321dadb3d98db78a9ef8c60c1614bf3aef6571e00b16d65b21d6864`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021919 ([`fda-drugs-nda021919-2009-10-30-638092117f89`](#source-fda-drugs-nda021919-2009-10-30-638092117f89))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021919 with status AP dated 2009-10-30, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda021919-2009-10-30-638092117f89`](#source-fda-drugs-nda021919-2009-10-30-638092117f89))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021919 with status AP dated 2009-10-30, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda021919-2009-10-30-638092117f89`](#source-fda-drugs-nda021919-2009-10-30-638092117f89))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021919-2009-10-30-638092117f89`](#source-fda-drugs-nda021919-2009-10-30-638092117f89))

### Sources

<a id="source-fda-drugs-nda021919-2009-10-30-638092117f89"></a>
- **Drugs@FDA application NDA021919 · original submission status AP · 2009-10-30 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021919%22&limit=1) (`fda-drugs-nda021919-2009-10-30-638092117f89`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021919." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda021919-v1 SHA-256: fbfc78fee321dadb3d98db78a9ef8c60c1614bf3aef6571e00b16d65b21d6864.

---

<a id="fda-drugs-nda022200-v1"></a>

## Drugs@FDA application NDA022200

> The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022200:v1`
- Evidence domain: Regulatory
- Date in source: 2012-01-27
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022200/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda022200-v1
- Content SHA-256: `25a83aff91f4f2a61cf0651d5262afe34a5855f53858d5c7e487108e880d3ee1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022200 ([`fda-drugs-nda022200-2012-01-27-454d1777c87f`](#source-fda-drugs-nda022200-2012-01-27-454d1777c87f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda022200-2012-01-27-454d1777c87f`](#source-fda-drugs-nda022200-2012-01-27-454d1777c87f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda022200-2012-01-27-454d1777c87f`](#source-fda-drugs-nda022200-2012-01-27-454d1777c87f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022200-2012-01-27-454d1777c87f`](#source-fda-drugs-nda022200-2012-01-27-454d1777c87f))

### Sources

<a id="source-fda-drugs-nda022200-2012-01-27-454d1777c87f"></a>
- **Drugs@FDA application NDA022200 · original submission status AP · 2012-01-27 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022200%22&limit=1) (`fda-drugs-nda022200-2012-01-27-454d1777c87f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022200." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda022200-v1 SHA-256: 25a83aff91f4f2a61cf0651d5262afe34a5855f53858d5c7e487108e880d3ee1.

---

<a id="fda-drugs-nda209210-v1"></a>

## Drugs@FDA application NDA209210

> The official Drugs@FDA dataset lists original submission 1 for NDA 209210 with status AP dated 2017-10-20, and names exenatide synthetic among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda209210:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-20
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda209210/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda209210-v1
- Content SHA-256: `af8961bb72f930b6b01555c04238644fba218e84a9bf361d1f0737b7b50a754f`

### Claims and source pins

#### Headline

Drugs@FDA application NDA209210 ([`fda-drugs-nda209210-2017-10-20-473b81562789`](#source-fda-drugs-nda209210-2017-10-20-473b81562789))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 209210 with status AP dated 2017-10-20, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda209210-2017-10-20-473b81562789`](#source-fda-drugs-nda209210-2017-10-20-473b81562789))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 209210 with status AP dated 2017-10-20, and names exenatide synthetic among the application record's active ingredients. ([`fda-drugs-nda209210-2017-10-20-473b81562789`](#source-fda-drugs-nda209210-2017-10-20-473b81562789))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda209210-2017-10-20-473b81562789`](#source-fda-drugs-nda209210-2017-10-20-473b81562789))

### Sources

<a id="source-fda-drugs-nda209210-2017-10-20-473b81562789"></a>
- **Drugs@FDA application NDA209210 · original submission status AP · 2017-10-20 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA209210%22&limit=1) (`fda-drugs-nda209210-2017-10-20-473b81562789`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA209210." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#fda-drugs-nda209210-v1 SHA-256: af8961bb72f930b6b01555c04238644fba218e84a9bf361d1f0737b7b50a754f.

---

<a id="federal-register-2021-18928-v1"></a>

## Federal Register notice 2021-18928

> The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2021-18928:v1`
- Evidence domain: Regulatory
- Date in source: 2021-09-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2021-18928/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2021-18928-v1
- Content SHA-256: `b3c97b85ca352ec85f8d6d28662db246935781605b32df9223974e97d43cf24a`

### Claims and source pins

#### Headline

Federal Register notice 2021-18928 ([`federal-register-2021-18928-8239c587d848`](#source-federal-register-2021-18928-8239c587d848))

#### Summary

The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2021-18928-8239c587d848`](#source-federal-register-2021-18928-8239c587d848))

#### Paragraph 1

The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2021-18928-8239c587d848`](#source-federal-register-2021-18928-8239c587d848))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2021-18928-8239c587d848`](#source-federal-register-2021-18928-8239c587d848))

### Sources

<a id="source-federal-register-2021-18928-8239c587d848"></a>
- **Federal Register notice 2021-18928 · published 2021-09-02 · Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2021-09-02/pdf/2021-18928.pdf) (`federal-register-2021-18928-8239c587d848`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2021-18928." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2021-18928-v1 SHA-256: b3c97b85ca352ec85f8d6d28662db246935781605b32df9223974e97d43cf24a.

---

<a id="federal-register-2022-10701-v1"></a>

## Federal Register notice 2022-10701

> The Federal Register published notice 2022-10701, attributed to FDA and its parent HHS department, on 2022-05-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.

- Evidence object: `story:federal-register-2022-10701:v1`
- Evidence domain: Regulatory
- Date in source: 2022-05-20
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-10701/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2022-10701-v1
- Content SHA-256: `fa26d807dcafb31afdb339603e8f5797f14567678e43fcb1b5142e1791e981ee`

### Claims and source pins

#### Headline

Federal Register notice 2022-10701 ([`federal-register-2022-10701-62e4a0d275fa`](#source-federal-register-2022-10701-62e4a0d275fa))

#### Summary

The Federal Register published notice 2022-10701, attributed to FDA and its parent HHS department, on 2022-05-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide. ([`federal-register-2022-10701-62e4a0d275fa`](#source-federal-register-2022-10701-62e4a0d275fa))

#### Paragraph 1

The Federal Register published notice 2022-10701, attributed to FDA and its parent HHS department, on 2022-05-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide. ([`federal-register-2022-10701-62e4a0d275fa`](#source-federal-register-2022-10701-62e4a0d275fa))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-10701-62e4a0d275fa`](#source-federal-register-2022-10701-62e4a0d275fa))

### Sources

<a id="source-federal-register-2022-10701-62e4a0d275fa"></a>
- **Federal Register notice 2022-10701 · published 2022-05-20 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-05-20/pdf/2022-10701.pdf) (`federal-register-2022-10701-62e4a0d275fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-10701." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2022-10701-v1 SHA-256: fa26d807dcafb31afdb339603e8f5797f14567678e43fcb1b5142e1791e981ee.

---

<a id="federal-register-2023-18241-v1"></a>

## Federal Register notice 2023-18241

> The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2023-18241:v1`
- Evidence domain: Regulatory
- Date in source: 2023-08-24
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-18241/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2023-18241-v1
- Content SHA-256: `d6ecd37245ce02e5c29300cee3fe8a05b51da751a3faf9500732f868d537728a`

### Claims and source pins

#### Headline

Federal Register notice 2023-18241 ([`federal-register-2023-18241-d6c92e8889c0`](#source-federal-register-2023-18241-d6c92e8889c0))

#### Summary

The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2023-18241-d6c92e8889c0`](#source-federal-register-2023-18241-d6c92e8889c0))

#### Paragraph 1

The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2023-18241-d6c92e8889c0`](#source-federal-register-2023-18241-d6c92e8889c0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-18241-d6c92e8889c0`](#source-federal-register-2023-18241-d6c92e8889c0))

### Sources

<a id="source-federal-register-2023-18241-d6c92e8889c0"></a>
- **Federal Register notice 2023-18241 · published 2023-08-24 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-08-24/pdf/2023-18241.pdf) (`federal-register-2023-18241-d6c92e8889c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-18241." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2023-18241-v1 SHA-256: d6ecd37245ce02e5c29300cee3fe8a05b51da751a3faf9500732f868d537728a.

---

<a id="federal-register-2023-18250-v1"></a>

## Federal Register notice 2023-18250

> The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2023-18250:v1`
- Evidence domain: Regulatory
- Date in source: 2023-08-24
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-18250/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2023-18250-v1
- Content SHA-256: `be4bef10466e661ba0e65a9c9a472841ff2a85c707ae09912521223d1d50eb4b`

### Claims and source pins

#### Headline

Federal Register notice 2023-18250 ([`federal-register-2023-18250-07d2e97e8788`](#source-federal-register-2023-18250-07d2e97e8788))

#### Summary

The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2023-18250-07d2e97e8788`](#source-federal-register-2023-18250-07d2e97e8788))

#### Paragraph 1

The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2023-18250-07d2e97e8788`](#source-federal-register-2023-18250-07d2e97e8788))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-18250-07d2e97e8788`](#source-federal-register-2023-18250-07d2e97e8788))

### Sources

<a id="source-federal-register-2023-18250-07d2e97e8788"></a>
- **Federal Register notice 2023-18250 · published 2023-08-24 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-08-24/pdf/2023-18250.pdf) (`federal-register-2023-18250-07d2e97e8788`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-18250." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2023-18250-v1 SHA-256: be4bef10466e661ba0e65a9c9a472841ff2a85c707ae09912521223d1d50eb4b.

---

<a id="federal-register-2024-18898-v1"></a>

## Federal Register notice 2024-18898

> The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon.

- Evidence object: `story:federal-register-2024-18898:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-23
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-18898/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2024-18898-v1
- Content SHA-256: `699ef5d26b2732f4fa30ac6870a8dc88fe1961cb5b7491facc888386d958dbe3`

### Claims and source pins

#### Headline

Federal Register notice 2024-18898 ([`federal-register-2024-18898-49e038727fed`](#source-federal-register-2024-18898-49e038727fed))

#### Summary

The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon. ([`federal-register-2024-18898-49e038727fed`](#source-federal-register-2024-18898-49e038727fed))

#### Paragraph 1

The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon. ([`federal-register-2024-18898-49e038727fed`](#source-federal-register-2024-18898-49e038727fed))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-18898-49e038727fed`](#source-federal-register-2024-18898-49e038727fed))

### Sources

<a id="source-federal-register-2024-18898-49e038727fed"></a>
- **Federal Register notice 2024-18898 · published 2024-08-23 · Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-08-23/pdf/2024-18898.pdf) (`federal-register-2024-18898-49e038727fed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-18898." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2024-18898-v1 SHA-256: 699ef5d26b2732f4fa30ac6870a8dc88fe1961cb5b7491facc888386d958dbe3.

---

<a id="federal-register-2025-14683-v1"></a>

## Federal Register notice 2025-14683

> The Federal Register published notice 2025-14683, attributed to FDA and its parent HHS department, on 2025-08-04. Its official title is “Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2025-14683:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-04
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-14683/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2025-14683-v1
- Content SHA-256: `7537cbe05fb901e7fcbe833f287f269897e3214417a8bdd9348a38d8299594c0`

### Claims and source pins

#### Headline

Federal Register notice 2025-14683 ([`federal-register-2025-14683-4261e4ef62ed`](#source-federal-register-2025-14683-4261e4ef62ed))

#### Summary

The Federal Register published notice 2025-14683, attributed to FDA and its parent HHS department, on 2025-08-04. Its official title is “Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2025-14683-4261e4ef62ed`](#source-federal-register-2025-14683-4261e4ef62ed))

#### Paragraph 1

The Federal Register published notice 2025-14683, attributed to FDA and its parent HHS department, on 2025-08-04. Its official title is “Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2025-14683-4261e4ef62ed`](#source-federal-register-2025-14683-4261e4ef62ed))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-14683-4261e4ef62ed`](#source-federal-register-2025-14683-4261e4ef62ed))

### Sources

<a id="source-federal-register-2025-14683-4261e4ef62ed"></a>
- **Federal Register notice 2025-14683 · published 2025-08-04 · Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-08-04/pdf/2025-14683.pdf) (`federal-register-2025-14683-4261e4ef62ed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-14683." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2025-14683-v1 SHA-256: 7537cbe05fb901e7fcbe833f287f269897e3214417a8bdd9348a38d8299594c0.

---

<a id="federal-register-2025-19281-v1"></a>

## Federal Register notice 2025-19281

> The Federal Register published notice 2025-19281, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.

- Evidence object: `story:federal-register-2025-19281:v1`
- Evidence domain: Regulatory
- Date in source: 2025-10-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-19281/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2025-19281-v1
- Content SHA-256: `6e422ed2a2c872d9f0198fbb7d3c10f122f2d2df608bc03d744f7b2d48758b12`

### Claims and source pins

#### Headline

Federal Register notice 2025-19281 ([`federal-register-2025-19281-a249d4879133`](#source-federal-register-2025-19281-a249d4879133))

#### Summary

The Federal Register published notice 2025-19281, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide. ([`federal-register-2025-19281-a249d4879133`](#source-federal-register-2025-19281-a249d4879133))

#### Paragraph 1

The Federal Register published notice 2025-19281, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide. ([`federal-register-2025-19281-a249d4879133`](#source-federal-register-2025-19281-a249d4879133))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-19281-a249d4879133`](#source-federal-register-2025-19281-a249d4879133))

### Sources

<a id="source-federal-register-2025-19281-a249d4879133"></a>
- **Federal Register notice 2025-19281 · published 2025-10-02 · Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-10-02/pdf/2025-19281.pdf) (`federal-register-2025-19281-a249d4879133`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-19281." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2025-19281-v1 SHA-256: 6e422ed2a2c872d9f0198fbb7d3c10f122f2d2df608bc03d744f7b2d48758b12.

---

<a id="federal-register-2026-04546-v1"></a>

## Federal Register notice 2026-04546

> The Federal Register published notice 2026-04546, attributed to FDA and its parent HHS department, on 2026-03-09. Its official title is “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2026-04546:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-09
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-04546/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2026-04546-v1
- Content SHA-256: `6af3fa33958cc7c60e960bb9b6d41bd51c43e64bf793532ec7b0f2472f669b50`

### Claims and source pins

#### Headline

Federal Register notice 2026-04546 ([`federal-register-2026-04546-40c461fd84fc`](#source-federal-register-2026-04546-40c461fd84fc))

#### Summary

The Federal Register published notice 2026-04546, attributed to FDA and its parent HHS department, on 2026-03-09. Its official title is “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2026-04546-40c461fd84fc`](#source-federal-register-2026-04546-40c461fd84fc))

#### Paragraph 1

The Federal Register published notice 2026-04546, attributed to FDA and its parent HHS department, on 2026-03-09. Its official title is “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2026-04546-40c461fd84fc`](#source-federal-register-2026-04546-40c461fd84fc))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-04546-40c461fd84fc`](#source-federal-register-2026-04546-40c461fd84fc))

### Sources

<a id="source-federal-register-2026-04546-40c461fd84fc"></a>
- **Federal Register notice 2026-04546 · published 2026-03-09 · Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-03-09/pdf/2026-04546.pdf) (`federal-register-2026-04546-40c461fd84fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-04546." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2026-04546-v1 SHA-256: 6af3fa33958cc7c60e960bb9b6d41bd51c43e64bf793532ec7b0f2472f669b50.

---

<a id="federal-register-2026-16998-v1"></a>

## Federal Register notice 2026-16998

> The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2026-16998:v1`
- Evidence domain: Regulatory
- Date in source: 2026-08-20
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-16998/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2026-16998-v1
- Content SHA-256: `03bf69990125777da6721b20401b2fbc3c38499478bb1bdf648facdbe2d43d4e`

### Claims and source pins

#### Headline

Federal Register notice 2026-16998 ([`federal-register-2026-16998-05e037fde43c`](#source-federal-register-2026-16998-05e037fde43c))

#### Summary

The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2026-16998-05e037fde43c`](#source-federal-register-2026-16998-05e037fde43c))

#### Paragraph 1

The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2026-16998-05e037fde43c`](#source-federal-register-2026-16998-05e037fde43c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-16998-05e037fde43c`](#source-federal-register-2026-16998-05e037fde43c))

### Sources

<a id="source-federal-register-2026-16998-05e037fde43c"></a>
- **Federal Register notice 2026-16998 · published 2026-08-20 · Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16998.pdf) (`federal-register-2026-16998-05e037fde43c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-16998." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2026-16998-v1 SHA-256: 03bf69990125777da6721b20401b2fbc3c38499478bb1bdf648facdbe2d43d4e.

---

<a id="federal-register-2026-23141-v1"></a>

## Federal Register notice 2026-23141

> The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-2026-23141:v1`
- Evidence domain: Regulatory
- Date in source: 2026-11-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-23141/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2026-23141-v1
- Content SHA-256: `dc31646386ed14395fb05ebf98409c79d88a3c299591e56051521cc8b491a9de`

### Claims and source pins

#### Headline

Federal Register notice 2026-23141 ([`federal-register-2026-23141-024f888bd7b4`](#source-federal-register-2026-23141-024f888bd7b4))

#### Summary

The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2026-23141-024f888bd7b4`](#source-federal-register-2026-23141-024f888bd7b4))

#### Paragraph 1

The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-2026-23141-024f888bd7b4`](#source-federal-register-2026-23141-024f888bd7b4))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-23141-024f888bd7b4`](#source-federal-register-2026-23141-024f888bd7b4))

### Sources

<a id="source-federal-register-2026-23141-024f888bd7b4"></a>
- **Federal Register notice 2026-23141 · published 2026-11-13 · Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-11-13/pdf/2026-23141.pdf) (`federal-register-2026-23141-024f888bd7b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-23141." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-2026-23141-v1 SHA-256: dc31646386ed14395fb05ebf98409c79d88a3c299591e56051521cc8b491a9de.

---

<a id="federal-register-e6-16086-v1"></a>

## Federal Register notice E6-16086

> The Federal Register published notice E6-16086, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

- Evidence object: `story:federal-register-e6-16086:v1`
- Evidence domain: Regulatory
- Date in source: 2006-10-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-16086/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-e6-16086-v1
- Content SHA-256: `db75214690e8b4ece5353678f3b7969da1a6eefbc685ad1429afbc29e2556707`

### Claims and source pins

#### Headline

Federal Register notice E6-16086 ([`federal-register-e6-16086-7caa57bff052`](#source-federal-register-e6-16086-7caa57bff052))

#### Summary

The Federal Register published notice E6-16086, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-e6-16086-7caa57bff052`](#source-federal-register-e6-16086-7caa57bff052))

#### Paragraph 1

The Federal Register published notice E6-16086, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide. ([`federal-register-e6-16086-7caa57bff052`](#source-federal-register-e6-16086-7caa57bff052))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-16086-7caa57bff052`](#source-federal-register-e6-16086-7caa57bff052))

### Sources

<a id="source-federal-register-e6-16086-7caa57bff052"></a>
- **Federal Register notice E6-16086 · published 2006-10-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16086.pdf) (`federal-register-e6-16086-7caa57bff052`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-16086." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#federal-register-e6-16086-v1 SHA-256: db75214690e8b4ece5353678f3b7969da1a6eefbc685ad1429afbc29e2556707.

---

<a id="pubmed-pmid-12808878-exenatide-v1"></a>

## Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.

> PubMed lists PMID 12808878 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-04 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12808878-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12808878-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-12808878-exenatide-v1
- Content SHA-256: `10e67bab17d25a6b2bde89541e8b6306b371635132d1a3abbb990ae365cd3d08`

### Claims and source pins

#### Headline

Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. ([`pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad`](#source-pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad))

#### Summary

PubMed lists PMID 12808878 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-04 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad`](#source-pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad))

#### Paragraph 1

PubMed lists PMID 12808878 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-04 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad`](#source-pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad`](#source-pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad))

### Sources

<a id="source-pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad"></a>
- **Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. · retained source version 1:2026-01-28:current:56aee5479aad90be2c853daa9797be77c4e3025f182e9ebb69a30bb03dc8316e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12808878/) (`pubmed-observation-pmid-12808878-2026-01-28-56aee5479aad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-12808878-exenatide-v1 SHA-256: 10e67bab17d25a6b2bde89541e8b6306b371635132d1a3abbb990ae365cd3d08.

---

<a id="pubmed-pmid-14702143-exenatide-v1"></a>

## Molecule of the month. Exenatide.

> PubMed lists PMID 14702143 in Drug news & perspectives as Journal Article, with publication-date metadata of 2003-11 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14702143-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14702143-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-14702143-exenatide-v1
- Content SHA-256: `fbd2ddddb26fe0825e59e72689ea8ee7b59cc19fcc96493ad080359f67dec4d5`

### Claims and source pins

#### Headline

Molecule of the month. Exenatide. ([`pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496`](#source-pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496))

#### Summary

PubMed lists PMID 14702143 in Drug news & perspectives as Journal Article, with publication-date metadata of 2003-11 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496`](#source-pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496))

#### Paragraph 1

PubMed lists PMID 14702143 in Drug news & perspectives as Journal Article, with publication-date metadata of 2003-11 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496`](#source-pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496`](#source-pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496))

### Sources

<a id="source-pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496"></a>
- **Molecule of the month. Exenatide. · retained source version 1:2018-11-30:current:0e77cf0c2496342a6c216f0af9ce59ef4aef0b8358bc0eb76fa5e0fcea3cfd3a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14702143/) (`pubmed-observation-pmid-14702143-2018-11-30-0e77cf0c2496`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Molecule of the month. Exenatide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-14702143-exenatide-v1 SHA-256: fbd2ddddb26fe0825e59e72689ea8ee7b59cc19fcc96493ad080359f67dec4d5.

---

<a id="pubmed-pmid-15831781-exenatide-v1"></a>

## Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.

> PubMed lists PMID 15831781 in Journal of clinical pharmacology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-05 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15831781-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15831781-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-15831781-exenatide-v1
- Content SHA-256: `c010c9790ff0bef709503ec41947dd847d49cfd7e526697059577ef11c9bf3db`

### Claims and source pins

#### Headline

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. ([`pubmed-observation-pmid-15831781-2018-12-01-3417253d5636`](#source-pubmed-observation-pmid-15831781-2018-12-01-3417253d5636))

#### Summary

PubMed lists PMID 15831781 in Journal of clinical pharmacology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-05 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15831781-2018-12-01-3417253d5636`](#source-pubmed-observation-pmid-15831781-2018-12-01-3417253d5636))

#### Paragraph 1

PubMed lists PMID 15831781 in Journal of clinical pharmacology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-05 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15831781-2018-12-01-3417253d5636`](#source-pubmed-observation-pmid-15831781-2018-12-01-3417253d5636))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15831781-2018-12-01-3417253d5636`](#source-pubmed-observation-pmid-15831781-2018-12-01-3417253d5636))

### Sources

<a id="source-pubmed-observation-pmid-15831781-2018-12-01-3417253d5636"></a>
- **Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. · retained source version 1:2018-12-01:current:3417253d56362f19fca77770d56c0bdcaa8f68ff88f2a441b18032416d6a15fe** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15831781/) (`pubmed-observation-pmid-15831781-2018-12-01-3417253d5636`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-15831781-exenatide-v1 SHA-256: c010c9790ff0bef709503ec41947dd847d49cfd7e526697059577ef11c9bf3db.

---

<a id="pubmed-pmid-15933616-exenatide-v1"></a>

## Exenatide (Byetta) for type 2 diabetes.

> PubMed lists PMID 15933616 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2005-06-06 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15933616-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15933616-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-15933616-exenatide-v1
- Content SHA-256: `e8957508e4ecd24a8694f425bcbc17fd1901b4ee675da593d8f2a4db7a078859`

### Claims and source pins

#### Headline

Exenatide (Byetta) for type 2 diabetes. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

#### Summary

PubMed lists PMID 15933616 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2005-06-06 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

#### Paragraph 1

PubMed lists PMID 15933616 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2005-06-06 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

### Sources

<a id="source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c"></a>
- **Exenatide (Byetta) for type 2 diabetes. · retained source version 1:2018-12-01:current:6048229a271c7fd1e3b2b62dbf6eef74b4edc308001d96c8891ffea7d1b572b1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15933616/) (`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide (Byetta) for type 2 diabetes." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-15933616-exenatide-v1 SHA-256: e8957508e4ecd24a8694f425bcbc17fd1901b4ee675da593d8f2a4db7a078859.

---

<a id="pubmed-pmid-16550880-exenatide-v1"></a>

## \[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\].

> PubMed lists PMID 16550880 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, Review, with publication-date metadata of 2006-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16550880-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16550880-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16550880-exenatide-v1
- Content SHA-256: `5e031aee302af771dfeb8c4bade6832bdd567101f647c5a00dd911e09f95e1b7`

### Claims and source pins

#### Headline

\[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\]. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

#### Summary

PubMed lists PMID 16550880 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, Review, with publication-date metadata of 2006-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

#### Paragraph 1

PubMed lists PMID 16550880 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, Review, with publication-date metadata of 2006-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

### Sources

<a id="source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133"></a>
- **\[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\]. · retained source version 1:2018-12-01:current:0e886ad4e133c39052a53c44640f6619f2b765ac7da98bf4fb21ed36b60a9e2a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16550880/) (`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16550880-exenatide-v1 SHA-256: 5e031aee302af771dfeb8c4bade6832bdd567101f647c5a00dd911e09f95e1b7.

---

<a id="pubmed-pmid-16610466-exenatide-v1"></a>

## Byetta (exenatide): what's your gut feeling?

> PubMed lists PMID 16610466 in South Dakota medicine : the journal of the South Dakota State Medical Association as Journal Article, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16610466-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16610466-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16610466-exenatide-v1
- Content SHA-256: `52654eed206798930e7606f62e26f60104c89beb69e2f627764a294ca63d294a`

### Claims and source pins

#### Headline

Byetta (exenatide): what's your gut feeling? ([`pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95`](#source-pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95))

#### Summary

PubMed lists PMID 16610466 in South Dakota medicine : the journal of the South Dakota State Medical Association as Journal Article, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95`](#source-pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95))

#### Paragraph 1

PubMed lists PMID 16610466 in South Dakota medicine : the journal of the South Dakota State Medical Association as Journal Article, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95`](#source-pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95`](#source-pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95))

### Sources

<a id="source-pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95"></a>
- **Byetta (exenatide): what's your gut feeling? · retained source version 1:2018-12-01:current:b421818cdf956f3b023acfccd580373e0f31b06866c0ee3fded5e0bfa2af74a6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16610466/) (`pubmed-observation-pmid-16610466-2018-12-01-b421818cdf95`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Byetta (exenatide): what's your gut feeling?" Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16610466-exenatide-v1 SHA-256: 52654eed206798930e7606f62e26f60104c89beb69e2f627764a294ca63d294a.

---

<a id="pubmed-pmid-16873820-exenatide-v1"></a>

## Clinical observations of exenatide treatment.

> PubMed lists PMID 16873820 in Diabetes care as Letter, with publication-date metadata of 2006-08 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16873820-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16873820-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16873820-exenatide-v1
- Content SHA-256: `ee2a71eb938f7166fb66103ccae73b437cd5743ac5f2c04da97cfff4c608b77a`

### Claims and source pins

#### Headline

Clinical observations of exenatide treatment. ([`pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835`](#source-pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835))

#### Summary

PubMed lists PMID 16873820 in Diabetes care as Letter, with publication-date metadata of 2006-08 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835`](#source-pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835))

#### Paragraph 1

PubMed lists PMID 16873820 in Diabetes care as Letter, with publication-date metadata of 2006-08 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835`](#source-pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835`](#source-pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835))

### Sources

<a id="source-pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835"></a>
- **Clinical observations of exenatide treatment. · retained source version 1:2018-12-01:current:dbd81a0f3835988a3e0ec34197012f3a9144a6c3b377e5ff9dc9793b4150e34b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16873820/) (`pubmed-observation-pmid-16873820-2018-12-01-dbd81a0f3835`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical observations of exenatide treatment." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16873820-exenatide-v1 SHA-256: ee2a71eb938f7166fb66103ccae73b437cd5743ac5f2c04da97cfff4c608b77a.

---

<a id="pubmed-pmid-16929370-exenatide-v1"></a>

## PubMed record PMID 16929370

> PeptideScanner retained PubMed bibliographic metadata for PMID 16929370 at 2026-07-30T22:50:21.672Z. PubMed recorded a metadata revision date of 2006-08-24 and an Entrez history date of 2006-08-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-16929370-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2006-08-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16929370-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16929370-exenatide-v1
- Content SHA-256: `73b7399b0e5c7901dc85ee67927a65be2dfbc91bb9e168f76eb5ce26cf4addff`

### Claims and source pins

#### Headline

PubMed record PMID 16929370 ([`pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f`](#source-pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 16929370 at 2026-07-30T22:50:21.672Z. PubMed recorded a metadata revision date of 2006-08-24 and an Entrez history date of 2006-08-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f`](#source-pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 16929370 at 2026-07-30T22:50:21.672Z. PubMed recorded a metadata revision date of 2006-08-24 and an Entrez history date of 2006-08-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f`](#source-pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f`](#source-pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f))

### Sources

<a id="source-pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f"></a>
- **PubMed record PMID 16929370 · retained source version 1:2006-08-24:current:9ff00e39339f85436d40f090b668549ec65760fd7160c93192a1013c2f0be6ec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16929370/) (`pubmed-observation-pmid-16929370-2006-08-24-9ff00e39339f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 16929370." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-16929370-exenatide-v1 SHA-256: 73b7399b0e5c7901dc85ee67927a65be2dfbc91bb9e168f76eb5ce26cf4addff.

---

<a id="pubmed-pmid-17404346-exenatide-v1"></a>

## Summaries for patients. Exenatide therapy for type 2 diabetes.

> PubMed lists PMID 17404346 in Annals of internal medicine as Journal Article, Patient Education Handout, with publication-date metadata of 2007-04-03 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17404346-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17404346-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17404346-exenatide-v1
- Content SHA-256: `fb9b1985bf71bb0262d8eb2854a691f76a07d3e296d2fdc6de5711655008954a`

### Claims and source pins

#### Headline

Summaries for patients. Exenatide therapy for type 2 diabetes. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

#### Summary

PubMed lists PMID 17404346 in Annals of internal medicine as Journal Article, Patient Education Handout, with publication-date metadata of 2007-04-03 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

#### Paragraph 1

PubMed lists PMID 17404346 in Annals of internal medicine as Journal Article, Patient Education Handout, with publication-date metadata of 2007-04-03 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

### Sources

<a id="source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e"></a>
- **Summaries for patients. Exenatide therapy for type 2 diabetes. · retained source version 1:2026-01-28:current:cafd6188ea6e31e5e24be5083ddd428cbf8512bb747aad863da81df1d22ae551** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17404346/) (`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Summaries for patients. Exenatide therapy for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17404346-exenatide-v1 SHA-256: fb9b1985bf71bb0262d8eb2854a691f76a07d3e296d2fdc6de5711655008954a.

---

<a id="pubmed-pmid-17595353-exenatide-v1"></a>

## Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

> PubMed lists PMID 17595353 in Diabetes care as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-06-26 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17595353-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17595353-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17595353-exenatide-v1
- Content SHA-256: `d8d34fd9c77c03c13a85a439f479886e29989c49a5ce9036d4b3749565ffbed3`

### Claims and source pins

#### Headline

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. ([`pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e`](#source-pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e))

#### Summary

PubMed lists PMID 17595353 in Diabetes care as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-06-26 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e`](#source-pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e))

#### Paragraph 1

PubMed lists PMID 17595353 in Diabetes care as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-06-26 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e`](#source-pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e`](#source-pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e))

### Sources

<a id="source-pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e"></a>
- **Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. · retained source version 1:2026-01-28:current:5d562581ca9eab78233953d470dbfb092da71c9ba9f57f22f7ac561137ab867a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17595353/) (`pubmed-observation-pmid-17595353-2026-01-28-5d562581ca9e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17595353-exenatide-v1 SHA-256: d8d34fd9c77c03c13a85a439f479886e29989c49a5ce9036d4b3749565ffbed3.

---

<a id="pubmed-pmid-17705687-exenatide-v1"></a>

## The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

> PubMed lists PMID 17705687 in Diabetes technology & therapeutics as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17705687-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17705687-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17705687-exenatide-v1
- Content SHA-256: `ab2ad23d0a27301a87450d3cee6e8b78c56398d36ebc66dbd493f4c53eba65dd`

### Claims and source pins

#### Headline

The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. ([`pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c`](#source-pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c))

#### Summary

PubMed lists PMID 17705687 in Diabetes technology & therapeutics as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c`](#source-pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c))

#### Paragraph 1

PubMed lists PMID 17705687 in Diabetes technology & therapeutics as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c`](#source-pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c`](#source-pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c))

### Sources

<a id="source-pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c"></a>
- **The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. · retained source version 1:2026-01-28:current:3e72b3fa3f9c4ebeaaeb4044c4fb990150d3ebd374a1924a88a38d065e11ef49** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17705687/) (`pubmed-observation-pmid-17705687-2026-01-28-3e72b3fa3f9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17705687-exenatide-v1 SHA-256: ab2ad23d0a27301a87450d3cee6e8b78c56398d36ebc66dbd493f4c53eba65dd.

---

<a id="pubmed-pmid-17872344-exenatide-v1"></a>

## Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.

> PubMed lists PMID 17872344 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, with publication-date metadata of 2007-09 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17872344-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17872344-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17872344-exenatide-v1
- Content SHA-256: `58b29e4a8786efc7ce6e181724ad4664c3a542157acf6e06deefb9f7312b0d3f`

### Claims and source pins

#### Headline

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. ([`pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf`](#source-pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf))

#### Summary

PubMed lists PMID 17872344 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, with publication-date metadata of 2007-09 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf`](#source-pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf))

#### Paragraph 1

PubMed lists PMID 17872344 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Journal Article, with publication-date metadata of 2007-09 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf`](#source-pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf`](#source-pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf))

### Sources

<a id="source-pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf"></a>
- **Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. · retained source version 1:2026-01-28:current:13f91960a2bfc7ea6f36d68aeaef25cd1898c5b1913268f9ea1f3dee2accf023** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17872344/) (`pubmed-observation-pmid-17872344-2026-01-28-13f91960a2bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-17872344-exenatide-v1 SHA-256: 58b29e4a8786efc7ce6e181724ad4664c3a542157acf6e06deefb9f7312b0d3f.

---

<a id="pubmed-pmid-18087791-exenatide-v1"></a>

## Exenatide: new drug. Type 2 diabetes for some overweight patients.

> PubMed lists PMID 18087791 in Prescrire international as Journal Article, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18087791-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18087791-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-18087791-exenatide-v1
- Content SHA-256: `3fefa5357fffa38b9f399a055143318a953c587f6bbc8c8e23843ecd8bacc063`

### Claims and source pins

#### Headline

Exenatide: new drug. Type 2 diabetes for some overweight patients. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

#### Summary

PubMed lists PMID 18087791 in Prescrire international as Journal Article, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

#### Paragraph 1

PubMed lists PMID 18087791 in Prescrire international as Journal Article, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

### Sources

<a id="source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2"></a>
- **Exenatide: new drug. Type 2 diabetes for some overweight patients. · retained source version 1:2026-01-28:current:e3ed84d60ac24d613a41e78ba8cee2d1361360f65c1f3b4d7d95e1a6aa4d1300** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18087791/) (`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide: new drug. Type 2 diabetes for some overweight patients." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-18087791-exenatide-v1 SHA-256: 3fefa5357fffa38b9f399a055143318a953c587f6bbc8c8e23843ecd8bacc063.

---

<a id="pubmed-pmid-18630353-exenatide-v1"></a>

## PubMed record PMID 18630353

> PeptideScanner retained PubMed bibliographic metadata for PMID 18630353 at 2026-07-30T22:38:13.928Z. PubMed recorded a metadata revision date of 2008-07-15 and an Entrez history date of 2008-07-17. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18630353-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2008-07-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18630353-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-18630353-exenatide-v1
- Content SHA-256: `e059da5f66f342753041516a25de223c8524719d2c1c63fd773d21c091ed0df9`

### Claims and source pins

#### Headline

PubMed record PMID 18630353 ([`pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9`](#source-pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18630353 at 2026-07-30T22:38:13.928Z. PubMed recorded a metadata revision date of 2008-07-15 and an Entrez history date of 2008-07-17. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9`](#source-pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18630353 at 2026-07-30T22:38:13.928Z. PubMed recorded a metadata revision date of 2008-07-15 and an Entrez history date of 2008-07-17. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9`](#source-pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9`](#source-pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9))

### Sources

<a id="source-pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9"></a>
- **PubMed record PMID 18630353 · retained source version 1:2008-07-15:current:94bc82d6eed95aff155545d3580f746a76a8a51257a172380b3518241cdc90ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18630353/) (`pubmed-observation-pmid-18630353-2008-07-15-94bc82d6eed9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18630353." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-18630353-exenatide-v1 SHA-256: e059da5f66f342753041516a25de223c8524719d2c1c63fd773d21c091ed0df9.

---

<a id="pubmed-pmid-18983211-exenatide-v1"></a>

## Exenatide and pancreatitis: an update.

> PubMed lists PMID 18983211 in Expert opinion on drug safety as Editorial, with publication-date metadata of 2008-11 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18983211-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18983211-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-18983211-exenatide-v1
- Content SHA-256: `1ed1ec268a56202b1715a7089dca1f65572e34045bbc85f7b1bbfb1e06cf326f`

### Claims and source pins

#### Headline

Exenatide and pancreatitis: an update. ([`pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1`](#source-pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1))

#### Summary

PubMed lists PMID 18983211 in Expert opinion on drug safety as Editorial, with publication-date metadata of 2008-11 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1`](#source-pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1))

#### Paragraph 1

PubMed lists PMID 18983211 in Expert opinion on drug safety as Editorial, with publication-date metadata of 2008-11 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1`](#source-pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1`](#source-pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1))

### Sources

<a id="source-pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1"></a>
- **Exenatide and pancreatitis: an update. · retained source version 1:2026-01-28:current:54f5137810d1149c3619815d4ad583b046d3848b46685094e362eddad2122a16** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18983211/) (`pubmed-observation-pmid-18983211-2026-01-28-54f5137810d1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide and pancreatitis: an update." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-18983211-exenatide-v1 SHA-256: 1ed1ec268a56202b1715a7089dca1f65572e34045bbc85f7b1bbfb1e06cf326f.

---

<a id="pubmed-pmid-19135608-exenatide-v1"></a>

## Exenatide for type 2 diabetes.

> PubMed lists PMID 19135608 in Lancet (London, England) as Letter, Comment, with publication-date metadata of 2009-01-10 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19135608-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19135608-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19135608-exenatide-v1
- Content SHA-256: `54a01a84626b4570f0e136bdf5fe17cb86e51bb09841039d33f2039f3a1296ee`

### Claims and source pins

#### Headline

Exenatide for type 2 diabetes. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

#### Summary

PubMed lists PMID 19135608 in Lancet (London, England) as Letter, Comment, with publication-date metadata of 2009-01-10 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

#### Paragraph 1

PubMed lists PMID 19135608 in Lancet (London, England) as Letter, Comment, with publication-date metadata of 2009-01-10 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

### Sources

<a id="source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb"></a>
- **Exenatide for type 2 diabetes. · retained source version 1:2026-01-28:current:b7ff3c5ddfdb7fccbcc4b7a8b8a04a5d019e7e020d953b3b76b81689fb7d98f2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19135608/) (`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19135608-exenatide-v1 SHA-256: 54a01a84626b4570f0e136bdf5fe17cb86e51bb09841039d33f2039f3a1296ee.

---

<a id="pubmed-pmid-19219409-exenatide-v1"></a>

## Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

> PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19219409-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19219409-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19219409-exenatide-v1
- Content SHA-256: `d7649c64cb4078ae227c18f449c02cf04635129420db144d6f5690f23c80ca18`

### Claims and source pins

#### Headline

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

#### Summary

PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

#### Paragraph 1

PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

### Sources

<a id="source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8"></a>
- **Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. · retained source version 1:2026-01-28:current:629863bb85d8032a9c1436928a15ec9f6730c0928d8fc669a8525b2be0a76df2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19219409/) (`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19219409-exenatide-v1 SHA-256: d7649c64cb4078ae227c18f449c02cf04635129420db144d6f5690f23c80ca18.

---

<a id="pubmed-pmid-19588557-exenatide-v1"></a>

## PubMed record PMID 19588557

> PeptideScanner retained PubMed bibliographic metadata for PMID 19588557 at 2026-07-30T22:27:39.924Z. PubMed recorded a metadata revision date of 2009-08-04 and an Entrez history date of 2009-07-10. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-19588557-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2009-08-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19588557-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19588557-exenatide-v1
- Content SHA-256: `24a76ffd0ee624978f33b7629c50533e487e40bb1cf66042fc75829ed41c509c`

### Claims and source pins

#### Headline

PubMed record PMID 19588557 ([`pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47`](#source-pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 19588557 at 2026-07-30T22:27:39.924Z. PubMed recorded a metadata revision date of 2009-08-04 and an Entrez history date of 2009-07-10. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47`](#source-pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 19588557 at 2026-07-30T22:27:39.924Z. PubMed recorded a metadata revision date of 2009-08-04 and an Entrez history date of 2009-07-10. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47`](#source-pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47`](#source-pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47))

### Sources

<a id="source-pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47"></a>
- **PubMed record PMID 19588557 · retained source version 1:2009-08-04:current:6e22a5d80f4714e0e47931d1677c2623bae36fad1470fce06025315b6201902b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19588557/) (`pubmed-observation-pmid-19588557-2009-08-04-6e22a5d80f47`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 19588557." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19588557-exenatide-v1 SHA-256: 24a76ffd0ee624978f33b7629c50533e487e40bb1cf66042fc75829ed41c509c.

---

<a id="pubmed-pmid-19695400-exenatide-v1"></a>

## Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.

> PubMed lists PMID 19695400 in Clinical therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19695400-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19695400-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19695400-exenatide-v1
- Content SHA-256: `a6979f4ede9f2891388c479baeaaa2980f50a7044183fcb7571d66efddc16d85`

### Claims and source pins

#### Headline

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. ([`pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce`](#source-pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce))

#### Summary

PubMed lists PMID 19695400 in Clinical therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce`](#source-pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce))

#### Paragraph 1

PubMed lists PMID 19695400 in Clinical therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce`](#source-pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce`](#source-pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce))

### Sources

<a id="source-pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce"></a>
- **Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. · retained source version 1:2026-01-28:current:ca85a2814dce3bd0a801a655ac3f1e3febee7257cafc2373dc517d339ff2cccb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19695400/) (`pubmed-observation-pmid-19695400-2026-01-28-ca85a2814dce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19695400-exenatide-v1 SHA-256: a6979f4ede9f2891388c479baeaaa2980f50a7044183fcb7571d66efddc16d85.

---

<a id="pubmed-pmid-19758357-exenatide-v1"></a>

## The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.

> PubMed lists PMID 19758357 in Diabetes, obesity & metabolism as Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-09-16 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19758357-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19758357-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19758357-exenatide-v1
- Content SHA-256: `94aac226d1533251cf18918641049f3bca1ebeed48be1847f02fce1fbeba21b9`

### Claims and source pins

#### Headline

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. ([`pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922`](#source-pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922))

#### Summary

PubMed lists PMID 19758357 in Diabetes, obesity & metabolism as Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-09-16 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922`](#source-pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922))

#### Paragraph 1

PubMed lists PMID 19758357 in Diabetes, obesity & metabolism as Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-09-16 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922`](#source-pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922`](#source-pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922))

### Sources

<a id="source-pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922"></a>
- **The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. · retained source version 1:2026-01-28:current:7c349d2f6922dcea2ae458915b5105a1f34566a9abc6397bad41a1e51f3f9085** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19758357/) (`pubmed-observation-pmid-19758357-2026-01-28-7c349d2f6922`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-19758357-exenatide-v1 SHA-256: 94aac226d1533251cf18918641049f3bca1ebeed48be1847f02fce1fbeba21b9.

---

<a id="pubmed-pmid-20022310-exenatide-v1"></a>

## Clinical experience with exenatide in a routine secondary care diabetes clinic.

> PubMed lists PMID 20022310 in Primary care diabetes as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20022310-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20022310-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20022310-exenatide-v1
- Content SHA-256: `dff1a98ea5a9c63ed14d9afccf92448e92155159003eb779f2f723dc7cd59b9f`

### Claims and source pins

#### Headline

Clinical experience with exenatide in a routine secondary care diabetes clinic. ([`pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c`](#source-pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c))

#### Summary

PubMed lists PMID 20022310 in Primary care diabetes as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c`](#source-pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c))

#### Paragraph 1

PubMed lists PMID 20022310 in Primary care diabetes as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c`](#source-pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c`](#source-pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c))

### Sources

<a id="source-pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c"></a>
- **Clinical experience with exenatide in a routine secondary care diabetes clinic. · retained source version 1:2026-01-28:current:481d7b86467c23bd88c7976b3045d357fecaa031e8e7844f45065d7213c299eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20022310/) (`pubmed-observation-pmid-20022310-2026-01-28-481d7b86467c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical experience with exenatide in a routine secondary care diabetes clinic." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20022310-exenatide-v1 SHA-256: dff1a98ea5a9c63ed14d9afccf92448e92155159003eb779f2f723dc7cd59b9f.

---

<a id="pubmed-pmid-20151774-exenatide-v1"></a>

## Exenatide versus glibenclamide in patients with diabetes.

> PubMed lists PMID 20151774 in Diabetes technology & therapeutics as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2010-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20151774-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20151774-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20151774-exenatide-v1
- Content SHA-256: `2a1ac026eab4ad1fd87afea2ab3614aeb23c3357ac06179aa5aedfd199c4a75b`

### Claims and source pins

#### Headline

Exenatide versus glibenclamide in patients with diabetes. ([`pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4`](#source-pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4))

#### Summary

PubMed lists PMID 20151774 in Diabetes technology & therapeutics as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2010-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4`](#source-pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4))

#### Paragraph 1

PubMed lists PMID 20151774 in Diabetes technology & therapeutics as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2010-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4`](#source-pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4`](#source-pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4))

### Sources

<a id="source-pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4"></a>
- **Exenatide versus glibenclamide in patients with diabetes. · retained source version 1:2026-01-28:current:b9f4825ef2a47516b448fceca29401213d1106f4fe375ab337ad60677293d8e4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20151774/) (`pubmed-observation-pmid-20151774-2026-01-28-b9f4825ef2a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exenatide versus glibenclamide in patients with diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20151774-exenatide-v1 SHA-256: 2a1ac026eab4ad1fd87afea2ab3614aeb23c3357ac06179aa5aedfd199c4a75b.

---

<a id="pubmed-pmid-20184107-exenatide-v1"></a>

## \[The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters\].

> PubMed lists PMID 20184107 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 2010-01 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20184107-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20184107-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20184107-exenatide-v1
- Content SHA-256: `824bf6c47d3dfb1971fe75dee83a43f4a0e5c078f06f17c3e34ef607bf169241`

### Claims and source pins

#### Headline

\[The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters\]. ([`pubmed-observation-pmid-20184107-2026-01-28-31afee16a582`](#source-pubmed-observation-pmid-20184107-2026-01-28-31afee16a582))

#### Summary

PubMed lists PMID 20184107 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 2010-01 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20184107-2026-01-28-31afee16a582`](#source-pubmed-observation-pmid-20184107-2026-01-28-31afee16a582))

#### Paragraph 1

PubMed lists PMID 20184107 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 2010-01 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20184107-2026-01-28-31afee16a582`](#source-pubmed-observation-pmid-20184107-2026-01-28-31afee16a582))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20184107-2026-01-28-31afee16a582`](#source-pubmed-observation-pmid-20184107-2026-01-28-31afee16a582))

### Sources

<a id="source-pubmed-observation-pmid-20184107-2026-01-28-31afee16a582"></a>
- **\[The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters\]. · retained source version 1:2026-01-28:current:31afee16a5824fbd33eee0647b8c80717425ad150ec35a3e9277cf163bee5cf5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20184107/) (`pubmed-observation-pmid-20184107-2026-01-28-31afee16a582`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20184107-exenatide-v1 SHA-256: 824bf6c47d3dfb1971fe75dee83a43f4a0e5c078f06f17c3e34ef607bf169241.

---

<a id="pubmed-pmid-20425675-exenatide-v1"></a>

## \[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes\].

> PubMed lists PMID 20425675 in Deutsche medizinische Wochenschrift (1946) as Case Reports, Journal Article, with publication-date metadata of 2010-04-27 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20425675-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20425675-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20425675-exenatide-v1
- Content SHA-256: `bfebaf93baf9c3d5e71055e6a5dd657097a5d352ceab5e4ea22196e1df47bd8f`

### Claims and source pins

#### Headline

\[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes\]. ([`pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482`](#source-pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482))

#### Summary

PubMed lists PMID 20425675 in Deutsche medizinische Wochenschrift (1946) as Case Reports, Journal Article, with publication-date metadata of 2010-04-27 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482`](#source-pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482))

#### Paragraph 1

PubMed lists PMID 20425675 in Deutsche medizinische Wochenschrift (1946) as Case Reports, Journal Article, with publication-date metadata of 2010-04-27 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482`](#source-pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482`](#source-pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482))

### Sources

<a id="source-pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482"></a>
- **\[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes\]. · retained source version 1:2026-01-28:current:6b325eeb5482ca234d241acf97c384a3f88361d4b89a98b901dd9a6864f3a320** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20425675/) (`pubmed-observation-pmid-20425675-2026-01-28-6b325eeb5482`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20425675-exenatide-v1 SHA-256: bfebaf93baf9c3d5e71055e6a5dd657097a5d352ceab5e4ea22196e1df47bd8f.

---

<a id="pubmed-pmid-20436114-exenatide-v1"></a>

## PubMed record PMID 20436114

> PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-20436114-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-02-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20436114-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20436114-exenatide-v1
- Content SHA-256: `b3270e45213782c2380289e71be6af5c4b2f21b458ed11f433145c7bb3184e7f`

### Claims and source pins

#### Headline

PubMed record PMID 20436114 ([`pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb`](#source-pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb`](#source-pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb`](#source-pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb`](#source-pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb))

### Sources

<a id="source-pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb"></a>
- **PubMed record PMID 20436114 · retained source version 1:2012-02-09:current:ebeabbfb5bcb1744826eeff48e4cfd47afec85caeef42436b8c87c4253344e91** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20436114/) (`pubmed-observation-pmid-20436114-2012-02-09-ebeabbfb5bcb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 20436114." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20436114-exenatide-v1 SHA-256: b3270e45213782c2380289e71be6af5c4b2f21b458ed11f433145c7bb3184e7f.

---

<a id="pubmed-pmid-20701787-exenatide-v1"></a>

## The use of exenatide in severely burned pediatric patients.

> PubMed lists PMID 20701787 in Critical care (London, England) as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2010-08-11 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20701787-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20701787-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20701787-exenatide-v1
- Content SHA-256: `c5497ea16aed0cde7a8678e155cff1010a1c3711a19edc30af4ff8e6ec9ec51a`

### Claims and source pins

#### Headline

The use of exenatide in severely burned pediatric patients. ([`pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52`](#source-pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52))

#### Summary

PubMed lists PMID 20701787 in Critical care (London, England) as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2010-08-11 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52`](#source-pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52))

#### Paragraph 1

PubMed lists PMID 20701787 in Critical care (London, England) as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2010-08-11 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52`](#source-pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52`](#source-pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52))

### Sources

<a id="source-pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52"></a>
- **The use of exenatide in severely burned pediatric patients. · retained source version 1:2026-01-30:current:7b0beb1fbf52b273a754c768e57936816d8a606457c5a5b5cf242be087ddd64f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20701787/) (`pubmed-observation-pmid-20701787-2026-01-30-7b0beb1fbf52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of exenatide in severely burned pediatric patients." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-20701787-exenatide-v1 SHA-256: c5497ea16aed0cde7a8678e155cff1010a1c3711a19edc30af4ff8e6ec9ec51a.

---

<a id="pubmed-pmid-22644981-exenatide-v1"></a>

## Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

> PubMed lists PMID 22644981 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Case Reports, Journal Article, with publication-date metadata of 2012-06-15 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22644981-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22644981-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-22644981-exenatide-v1
- Content SHA-256: `5f5b41d119f9223b5685cc9e2a19e82776c376815fff001906f56a6e4e9e3d69`

### Claims and source pins

#### Headline

Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

#### Summary

PubMed lists PMID 22644981 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Case Reports, Journal Article, with publication-date metadata of 2012-06-15 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

#### Paragraph 1

PubMed lists PMID 22644981 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Case Reports, Journal Article, with publication-date metadata of 2012-06-15 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

### Sources

<a id="source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a"></a>
- **Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. · retained source version 1:2026-01-28:current:fdde71a7649a1e8bc2a077f249cc29070823950a8de8b4d8960898257e4d5f99** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22644981/) (`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-22644981-exenatide-v1 SHA-256: 5f5b41d119f9223b5685cc9e2a19e82776c376815fff001906f56a6e4e9e3d69.

---

<a id="pubmed-pmid-22753275-exenatide-v1"></a>

## PubMed record PMID 22753275

> PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22753275-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-08-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22753275-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-22753275-exenatide-v1
- Content SHA-256: `b95271fe021065bb871a6c22cc517663b373b0a266a58b03bff0e10323906232`

### Claims and source pins

#### Headline

PubMed record PMID 22753275 ([`pubmed-observation-pmid-22753275-2012-08-23-89959dade87b`](#source-pubmed-observation-pmid-22753275-2012-08-23-89959dade87b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22753275-2012-08-23-89959dade87b`](#source-pubmed-observation-pmid-22753275-2012-08-23-89959dade87b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22753275-2012-08-23-89959dade87b`](#source-pubmed-observation-pmid-22753275-2012-08-23-89959dade87b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22753275-2012-08-23-89959dade87b`](#source-pubmed-observation-pmid-22753275-2012-08-23-89959dade87b))

### Sources

<a id="source-pubmed-observation-pmid-22753275-2012-08-23-89959dade87b"></a>
- **PubMed record PMID 22753275 · retained source version 1:2012-08-23:current:89959dade87b6e6f6821cdb4a7300c1a45c7613b0e4e6383726dbad57ed457fd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22753275/) (`pubmed-observation-pmid-22753275-2012-08-23-89959dade87b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22753275." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-22753275-exenatide-v1 SHA-256: b95271fe021065bb871a6c22cc517663b373b0a266a58b03bff0e10323906232.

---

<a id="pubmed-pmid-22997980-exenatide-v1"></a>

## PubMed record PMID 22997980

> PeptideScanner retained PubMed bibliographic metadata for PMID 22997980 at 2026-07-30T21:41:09.514Z. PubMed recorded a metadata revision date of 2015-11-19 and an Entrez history date of 2012-09-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22997980-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22997980-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-22997980-exenatide-v1
- Content SHA-256: `cfac867065daba8457a561748357593d092506f797459c9ed01d19af252d6b47`

### Claims and source pins

#### Headline

PubMed record PMID 22997980 ([`pubmed-observation-pmid-22997980-2015-11-19-682375608323`](#source-pubmed-observation-pmid-22997980-2015-11-19-682375608323))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22997980 at 2026-07-30T21:41:09.514Z. PubMed recorded a metadata revision date of 2015-11-19 and an Entrez history date of 2012-09-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22997980-2015-11-19-682375608323`](#source-pubmed-observation-pmid-22997980-2015-11-19-682375608323))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22997980 at 2026-07-30T21:41:09.514Z. PubMed recorded a metadata revision date of 2015-11-19 and an Entrez history date of 2012-09-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22997980-2015-11-19-682375608323`](#source-pubmed-observation-pmid-22997980-2015-11-19-682375608323))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22997980-2015-11-19-682375608323`](#source-pubmed-observation-pmid-22997980-2015-11-19-682375608323))

### Sources

<a id="source-pubmed-observation-pmid-22997980-2015-11-19-682375608323"></a>
- **PubMed record PMID 22997980 · retained source version 1:2015-11-19:current:6823756083234c25c303d9e17ceb68dc1daf67e9d340f276d223651c936e5795** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22997980/) (`pubmed-observation-pmid-22997980-2015-11-19-682375608323`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22997980." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-22997980-exenatide-v1 SHA-256: cfac867065daba8457a561748357593d092506f797459c9ed01d19af252d6b47.

---

<a id="pubmed-pmid-23039898-exenatide-v1"></a>

## Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens.

> PubMed lists PMID 23039898 in The American journal of managed care as Comparative Study, Journal Article, with publication-date metadata of 2012-09 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23039898-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23039898-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-23039898-exenatide-v1
- Content SHA-256: `4ba581125cf06677470aba936f8f006f71431ce48fe2563b2c137878c48275fd`

### Claims and source pins

#### Headline

Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens. ([`pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0`](#source-pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0))

#### Summary

PubMed lists PMID 23039898 in The American journal of managed care as Comparative Study, Journal Article, with publication-date metadata of 2012-09 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0`](#source-pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0))

#### Paragraph 1

PubMed lists PMID 23039898 in The American journal of managed care as Comparative Study, Journal Article, with publication-date metadata of 2012-09 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0`](#source-pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0`](#source-pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0))

### Sources

<a id="source-pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0"></a>
- **Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens. · retained source version 1:2026-01-28:current:43ea9aa337d09491cbb0dfc2ecce0ce50228a7f93515d35fd46369af867726dd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23039898/) (`pubmed-observation-pmid-23039898-2026-01-28-43ea9aa337d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-23039898-exenatide-v1 SHA-256: 4ba581125cf06677470aba936f8f006f71431ce48fe2563b2c137878c48275fd.

---

<a id="pubmed-pmid-25998595-exenatide-v1"></a>

## PubMed record PMID 25998595

> PeptideScanner retained PubMed bibliographic metadata for PMID 25998595 at 2026-07-30T21:43:30.962Z. PubMed recorded a metadata revision date of 2015-05-22 and an Entrez history date of 2015-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-25998595-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25998595-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-25998595-exenatide-v1
- Content SHA-256: `31a2b9bd8365efb668ffc2475595a104a9d295573c701eae81f64beb01dde6e7`

### Claims and source pins

#### Headline

PubMed record PMID 25998595 ([`pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e`](#source-pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 25998595 at 2026-07-30T21:43:30.962Z. PubMed recorded a metadata revision date of 2015-05-22 and an Entrez history date of 2015-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e`](#source-pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 25998595 at 2026-07-30T21:43:30.962Z. PubMed recorded a metadata revision date of 2015-05-22 and an Entrez history date of 2015-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e`](#source-pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e`](#source-pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e))

### Sources

<a id="source-pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e"></a>
- **PubMed record PMID 25998595 · retained source version 1:2015-05-22:current:f4ae2705406e2bb354dc1cbe880ede86ab6d16ba9f2538e25d130540f65b4c97** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25998595/) (`pubmed-observation-pmid-25998595-2015-05-22-f4ae2705406e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 25998595." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-25998595-exenatide-v1 SHA-256: 31a2b9bd8365efb668ffc2475595a104a9d295573c701eae81f64beb01dde6e7.

---

<a id="pubmed-pmid-27200638-exenatide-v1"></a>

## PubMed record PMID 27200638

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200638 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200638-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200638-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200638-exenatide-v1
- Content SHA-256: `622695abce9bbb5129075c73b87e315c0f54a6e144063be7724109d7e52fc514`

### Claims and source pins

#### Headline

PubMed record PMID 27200638 ([`pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085`](#source-pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200638 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085`](#source-pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200638 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085`](#source-pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085`](#source-pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085))

### Sources

<a id="source-pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085"></a>
- **PubMed record PMID 27200638 · retained source version 1:2016-05-21:current:bd5ab2899085891ac0b2608a9f1a93c3a47b08fdc665fb308e252cac04a77911** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200638/) (`pubmed-observation-pmid-27200638-2016-05-21-bd5ab2899085`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200638." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200638-exenatide-v1 SHA-256: 622695abce9bbb5129075c73b87e315c0f54a6e144063be7724109d7e52fc514.

---

<a id="pubmed-pmid-27200644-exenatide-v1"></a>

## PubMed record PMID 27200644

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200644 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200644-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200644-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200644-exenatide-v1
- Content SHA-256: `2dee2f34437815f9543405c5eeb003974fedab5f4e6fc0bfb208d9242666215d`

### Claims and source pins

#### Headline

PubMed record PMID 27200644 ([`pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3`](#source-pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200644 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3`](#source-pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200644 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3`](#source-pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3`](#source-pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3))

### Sources

<a id="source-pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3"></a>
- **PubMed record PMID 27200644 · retained source version 1:2016-05-21:current:2640a2dfaaa3b0cda97c797716e7cc26f1f64cb047a649839ff13e896ecfd744** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200644/) (`pubmed-observation-pmid-27200644-2016-05-21-2640a2dfaaa3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200644." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200644-exenatide-v1 SHA-256: 2dee2f34437815f9543405c5eeb003974fedab5f4e6fc0bfb208d9242666215d.

---

<a id="pubmed-pmid-27200645-exenatide-v1"></a>

## PubMed record PMID 27200645

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200645 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200645-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200645-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200645-exenatide-v1
- Content SHA-256: `8e361eba10d821cbfba18eda7e5ed58793fa7730d449db4a9b98d5cbdcd4be6d`

### Claims and source pins

#### Headline

PubMed record PMID 27200645 ([`pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869`](#source-pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200645 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869`](#source-pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200645 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869`](#source-pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869`](#source-pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869))

### Sources

<a id="source-pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869"></a>
- **PubMed record PMID 27200645 · retained source version 1:2016-05-21:current:3a8a3e576869427c61398fe0d74d8c78522da6dd21b30fdfea475ff529ca7e21** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200645/) (`pubmed-observation-pmid-27200645-2016-05-21-3a8a3e576869`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200645." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200645-exenatide-v1 SHA-256: 8e361eba10d821cbfba18eda7e5ed58793fa7730d449db4a9b98d5cbdcd4be6d.

---

<a id="pubmed-pmid-27200672-exenatide-v1"></a>

## PubMed record PMID 27200672

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200672 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200672-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200672-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200672-exenatide-v1
- Content SHA-256: `f6452db5e0b78600f1ecf911a73d3f181d670ecd42bd33d3317dab7ccb137435`

### Claims and source pins

#### Headline

PubMed record PMID 27200672 ([`pubmed-observation-pmid-27200672-2016-05-21-17359823d129`](#source-pubmed-observation-pmid-27200672-2016-05-21-17359823d129))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200672 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200672-2016-05-21-17359823d129`](#source-pubmed-observation-pmid-27200672-2016-05-21-17359823d129))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200672 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200672-2016-05-21-17359823d129`](#source-pubmed-observation-pmid-27200672-2016-05-21-17359823d129))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200672-2016-05-21-17359823d129`](#source-pubmed-observation-pmid-27200672-2016-05-21-17359823d129))

### Sources

<a id="source-pubmed-observation-pmid-27200672-2016-05-21-17359823d129"></a>
- **PubMed record PMID 27200672 · retained source version 1:2016-05-21:current:17359823d1294c0736dcc9ba448e713d375c296331324d96b7c1571eeb3231d0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200672/) (`pubmed-observation-pmid-27200672-2016-05-21-17359823d129`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200672." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200672-exenatide-v1 SHA-256: f6452db5e0b78600f1ecf911a73d3f181d670ecd42bd33d3317dab7ccb137435.

---

<a id="pubmed-pmid-27200673-exenatide-v1"></a>

## PubMed record PMID 27200673

> PeptideScanner retained PubMed bibliographic metadata for PMID 27200673 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27200673-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-05-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27200673-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200673-exenatide-v1
- Content SHA-256: `f381f1069043598fc9ed16ab34231ec53809e57afacb0f25f4e716ee6eb4b2af`

### Claims and source pins

#### Headline

PubMed record PMID 27200673 ([`pubmed-observation-pmid-27200673-2016-05-21-b3d695703333`](#source-pubmed-observation-pmid-27200673-2016-05-21-b3d695703333))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27200673 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200673-2016-05-21-b3d695703333`](#source-pubmed-observation-pmid-27200673-2016-05-21-b3d695703333))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27200673 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27200673-2016-05-21-b3d695703333`](#source-pubmed-observation-pmid-27200673-2016-05-21-b3d695703333))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27200673-2016-05-21-b3d695703333`](#source-pubmed-observation-pmid-27200673-2016-05-21-b3d695703333))

### Sources

<a id="source-pubmed-observation-pmid-27200673-2016-05-21-b3d695703333"></a>
- **PubMed record PMID 27200673 · retained source version 1:2016-05-21:current:b3d695703333fa31ca7caa22cd885b0a997c57033d72897cb949e00e2b590bf7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27200673/) (`pubmed-observation-pmid-27200673-2016-05-21-b3d695703333`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27200673." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-27200673-exenatide-v1 SHA-256: f381f1069043598fc9ed16ab34231ec53809e57afacb0f25f4e716ee6eb4b2af.

---

<a id="pubmed-pmid-30974038-exenatide-v1"></a>

## PubMed record PMID 30974038

> PeptideScanner retained PubMed bibliographic metadata for PMID 30974038 at 2026-08-10T10:49:06.835Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2019-04-12. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-30974038-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30974038-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-30974038-exenatide-v1
- Content SHA-256: `5df2c129067cbad7df344b85601a5a2d9584616a272dac54bf580f3dfee76bb4`

### Claims and source pins

#### Headline

PubMed record PMID 30974038 ([`pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb`](#source-pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 30974038 at 2026-08-10T10:49:06.835Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2019-04-12. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb`](#source-pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 30974038 at 2026-08-10T10:49:06.835Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2019-04-12. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb`](#source-pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb`](#source-pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb))

### Sources

<a id="source-pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb"></a>
- **PubMed record PMID 30974038 · retained source version 1:2026-08-08:current:1d561fa9f7fb2c05fe621cf301648e5b7faaaabcf317631af778bc198dc05e62** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30974038/) (`pubmed-observation-pmid-30974038-2026-08-08-1d561fa9f7fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 30974038." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-30974038-exenatide-v1 SHA-256: 5df2c129067cbad7df344b85601a5a2d9584616a272dac54bf580f3dfee76bb4.

---

<a id="pubmed-pmid-39805462-exenatide-v1"></a>

## PubMed record PMID 39805462

> PeptideScanner retained PubMed bibliographic metadata for PMID 39805462 at 2026-07-30T16:14:08.923Z. PubMed recorded a metadata revision date of 2026-06-10 and an Entrez history date of 2025-01-13. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39805462-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39805462-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-39805462-exenatide-v1
- Content SHA-256: `2036046d7d2fe75721be64f60f19ea700618098b0607d587ccbbd53bfc9ebe36`

### Claims and source pins

#### Headline

PubMed record PMID 39805462 ([`pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8`](#source-pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39805462 at 2026-07-30T16:14:08.923Z. PubMed recorded a metadata revision date of 2026-06-10 and an Entrez history date of 2025-01-13. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8`](#source-pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39805462 at 2026-07-30T16:14:08.923Z. PubMed recorded a metadata revision date of 2026-06-10 and an Entrez history date of 2025-01-13. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8`](#source-pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8`](#source-pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8))

### Sources

<a id="source-pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8"></a>
- **PubMed record PMID 39805462 · retained source version 1:2026-06-10:current:e9907b3af9e8ffc2c728d9f7c69cd36b6828259bae72b05fa3b4d5bbdc853f92** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39805462/) (`pubmed-observation-pmid-39805462-2026-06-10-e9907b3af9e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39805462." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-39805462-exenatide-v1 SHA-256: 2036046d7d2fe75721be64f60f19ea700618098b0607d587ccbbd53bfc9ebe36.

---

<a id="pubmed-pmid-39919773-exenatide-v1"></a>

## PubMed record PMID 39919773

> PeptideScanner retained PubMed bibliographic metadata for PMID 39919773 at 2026-07-30T16:14:10.828Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2025-02-07. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39919773-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39919773-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-39919773-exenatide-v1
- Content SHA-256: `c74b3fa082ed623d3995e879ee0762501288ce9584deaf86027349aaf00c0dbe`

### Claims and source pins

#### Headline

PubMed record PMID 39919773 ([`pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e`](#source-pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39919773 at 2026-07-30T16:14:10.828Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2025-02-07. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e`](#source-pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39919773 at 2026-07-30T16:14:10.828Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2025-02-07. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e`](#source-pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e`](#source-pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e))

### Sources

<a id="source-pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e"></a>
- **PubMed record PMID 39919773 · retained source version 1:2026-06-25:current:f60404d7e11e5948ff6f87b6352c857dbf7a49030e6ea3cd6f6c85aaec16fd2c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39919773/) (`pubmed-observation-pmid-39919773-2026-06-25-f60404d7e11e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39919773." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-39919773-exenatide-v1 SHA-256: c74b3fa082ed623d3995e879ee0762501288ce9584deaf86027349aaf00c0dbe.

---

<a id="pubmed-pmid-40246242-exenatide-v1"></a>

## PubMed record PMID 40246242

> PeptideScanner retained PubMed bibliographic metadata for PMID 40246242 at 2026-07-30T16:14:10.971Z. PubMed recorded a metadata revision date of 2026-06-21 and an Entrez history date of 2025-04-17. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40246242-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40246242-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-40246242-exenatide-v1
- Content SHA-256: `678dab5cde4df747a4896bc9c4c4548d24b38e09b2d61fb7749780a3ec5bc1a2`

### Claims and source pins

#### Headline

PubMed record PMID 40246242 ([`pubmed-observation-pmid-40246242-2026-06-21-b560317e6895`](#source-pubmed-observation-pmid-40246242-2026-06-21-b560317e6895))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40246242 at 2026-07-30T16:14:10.971Z. PubMed recorded a metadata revision date of 2026-06-21 and an Entrez history date of 2025-04-17. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40246242-2026-06-21-b560317e6895`](#source-pubmed-observation-pmid-40246242-2026-06-21-b560317e6895))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40246242 at 2026-07-30T16:14:10.971Z. PubMed recorded a metadata revision date of 2026-06-21 and an Entrez history date of 2025-04-17. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40246242-2026-06-21-b560317e6895`](#source-pubmed-observation-pmid-40246242-2026-06-21-b560317e6895))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40246242-2026-06-21-b560317e6895`](#source-pubmed-observation-pmid-40246242-2026-06-21-b560317e6895))

### Sources

<a id="source-pubmed-observation-pmid-40246242-2026-06-21-b560317e6895"></a>
- **PubMed record PMID 40246242 · retained source version 1:2026-06-21:current:b560317e6895d86f0070201652dbb51038d4ba89eaeb763ec7fe490bcf4d93c9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40246242/) (`pubmed-observation-pmid-40246242-2026-06-21-b560317e6895`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40246242." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-40246242-exenatide-v1 SHA-256: 678dab5cde4df747a4896bc9c4c4548d24b38e09b2d61fb7749780a3ec5bc1a2.

---

<a id="pubmed-pmid-41364402-exenatide-v1"></a>

## PubMed record PMID 41364402

> PeptideScanner retained PubMed bibliographic metadata for PMID 41364402 at 2026-08-10T18:13:38.016Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2025-12-09. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41364402-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41364402-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-41364402-exenatide-v1
- Content SHA-256: `a6a41cfa44fa08277f0591970637eb033c2726d480e4800f5e234c1829d49f15`

### Claims and source pins

#### Headline

PubMed record PMID 41364402 ([`pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9`](#source-pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41364402 at 2026-08-10T18:13:38.016Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2025-12-09. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9`](#source-pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41364402 at 2026-08-10T18:13:38.016Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2025-12-09. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9`](#source-pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9`](#source-pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9))

### Sources

<a id="source-pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9"></a>
- **PubMed record PMID 41364402 · retained source version 1:2026-07-26:current:d849b47f46f9d62ac59a6b2517ecf328ab66987091ae02b0c1d1fb83db8763cc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41364402/) (`pubmed-observation-pmid-41364402-2026-07-26-d849b47f46f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41364402." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-41364402-exenatide-v1 SHA-256: a6a41cfa44fa08277f0591970637eb033c2726d480e4800f5e234c1829d49f15.

---

<a id="pubmed-pmid-41597428-exenatide-v1"></a>

## PubMed record PMID 41597428

> PeptideScanner retained PubMed bibliographic metadata for PMID 41597428 at 2026-07-30T16:11:44.888Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41597428-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41597428-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-41597428-exenatide-v1
- Content SHA-256: `e23f1eb604795c52ca9c17d38f5c55661070fb3c39ef36ce99bbac346d3ec707`

### Claims and source pins

#### Headline

PubMed record PMID 41597428 ([`pubmed-observation-pmid-41597428-2026-07-01-158774816aed`](#source-pubmed-observation-pmid-41597428-2026-07-01-158774816aed))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41597428 at 2026-07-30T16:11:44.888Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41597428-2026-07-01-158774816aed`](#source-pubmed-observation-pmid-41597428-2026-07-01-158774816aed))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41597428 at 2026-07-30T16:11:44.888Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41597428-2026-07-01-158774816aed`](#source-pubmed-observation-pmid-41597428-2026-07-01-158774816aed))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41597428-2026-07-01-158774816aed`](#source-pubmed-observation-pmid-41597428-2026-07-01-158774816aed))

### Sources

<a id="source-pubmed-observation-pmid-41597428-2026-07-01-158774816aed"></a>
- **PubMed record PMID 41597428 · retained source version 1:2026-07-01:current:158774816aed8629649d780e99c7a0fc2a082a123846c68fe0287821cc5517e6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41597428/) (`pubmed-observation-pmid-41597428-2026-07-01-158774816aed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41597428." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-41597428-exenatide-v1 SHA-256: e23f1eb604795c52ca9c17d38f5c55661070fb3c39ef36ce99bbac346d3ec707.

---

<a id="pubmed-pmid-41865922-exenatide-v1"></a>

## PubMed record PMID 41865922

> PeptideScanner retained PubMed bibliographic metadata for PMID 41865922 at 2026-08-10T18:13:44.869Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-03-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41865922-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-13
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41865922-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-41865922-exenatide-v1
- Content SHA-256: `0b839af516e2e07eae85a7bc38a5d290df13111e343e09e37af0c5baa5b01ade`

### Claims and source pins

#### Headline

PubMed record PMID 41865922 ([`pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500`](#source-pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41865922 at 2026-08-10T18:13:44.869Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-03-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500`](#source-pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41865922 at 2026-08-10T18:13:44.869Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-03-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500`](#source-pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500`](#source-pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500))

### Sources

<a id="source-pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500"></a>
- **PubMed record PMID 41865922 · retained source version 1:2026-07-13:current:47f29b9d1500de0fe9f7b96f055382dabdf990445935a9f753bc2b13b081f97d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41865922/) (`pubmed-observation-pmid-41865922-2026-07-13-47f29b9d1500`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41865922." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-41865922-exenatide-v1 SHA-256: 0b839af516e2e07eae85a7bc38a5d290df13111e343e09e37af0c5baa5b01ade.

---

<a id="pubmed-pmid-42171611-exenatide-v1"></a>

## PubMed record PMID 42171611

> PeptideScanner retained PubMed bibliographic metadata for PMID 42171611 at 2026-08-10T18:13:50.652Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42171611-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42171611-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42171611-exenatide-v1
- Content SHA-256: `42a2950552a51ad4bd3f5723eac7c91bded7633a75ecd3b805cb965fc466246a`

### Claims and source pins

#### Headline

PubMed record PMID 42171611 ([`pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987`](#source-pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42171611 at 2026-08-10T18:13:50.652Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987`](#source-pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42171611 at 2026-08-10T18:13:50.652Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987`](#source-pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987`](#source-pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987))

### Sources

<a id="source-pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987"></a>
- **PubMed record PMID 42171611 · retained source version 1:2026-07-26:current:6f99eedab987d3e556e59b27c2c91619788736ac896600d4b2fdbf573c770d42** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42171611/) (`pubmed-observation-pmid-42171611-2026-07-26-6f99eedab987`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42171611." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42171611-exenatide-v1 SHA-256: 42a2950552a51ad4bd3f5723eac7c91bded7633a75ecd3b805cb965fc466246a.

---

<a id="pubmed-pmid-42175654-exenatide-v1"></a>

## PubMed record PMID 42175654

> PeptideScanner retained PubMed bibliographic metadata for PMID 42175654 at 2026-07-30T16:20:45.825Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42175654-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42175654-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42175654-exenatide-v1
- Content SHA-256: `e84ae58d74e60fae9a403bf82246869ec39e0f4e3b9228225fb3022288e37529`

### Claims and source pins

#### Headline

PubMed record PMID 42175654 ([`pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392`](#source-pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42175654 at 2026-07-30T16:20:45.825Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392`](#source-pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42175654 at 2026-07-30T16:20:45.825Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392`](#source-pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392`](#source-pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392))

### Sources

<a id="source-pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392"></a>
- **PubMed record PMID 42175654 · retained source version 1:2026-05-30:current:76c838f5e392be28bac2cf4ca2ef855dab58bf0a94175edaa54c1b31012ad93a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42175654/) (`pubmed-observation-pmid-42175654-2026-05-30-76c838f5e392`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42175654." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42175654-exenatide-v1 SHA-256: e84ae58d74e60fae9a403bf82246869ec39e0f4e3b9228225fb3022288e37529.

---

<a id="pubmed-pmid-42217255-exenatide-v1"></a>

## PubMed record PMID 42217255

> PeptideScanner retained PubMed bibliographic metadata for PMID 42217255 at 2026-07-30T16:20:46.631Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-30. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42217255-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42217255-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42217255-exenatide-v1
- Content SHA-256: `dedfcc43c45fa8692961ae3bc6c609b7dcf5249e47d32a2cb00a72d355994ac0`

### Claims and source pins

#### Headline

PubMed record PMID 42217255 ([`pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1`](#source-pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42217255 at 2026-07-30T16:20:46.631Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-30. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1`](#source-pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42217255 at 2026-07-30T16:20:46.631Z. PubMed recorded a metadata revision date of 2026-05-30 and an Entrez history date of 2026-05-30. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1`](#source-pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1`](#source-pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1))

### Sources

<a id="source-pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1"></a>
- **PubMed record PMID 42217255 · retained source version 1:2026-05-30:current:8df690ad8ba175709ee6a2de868a9d5a8a570cea815d5bf1069799bcda06aee6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42217255/) (`pubmed-observation-pmid-42217255-2026-05-30-8df690ad8ba1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42217255." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42217255-exenatide-v1 SHA-256: dedfcc43c45fa8692961ae3bc6c609b7dcf5249e47d32a2cb00a72d355994ac0.

---

<a id="pubmed-pmid-42290292-exenatide-v1"></a>

## PubMed record PMID 42290292

> PeptideScanner retained PubMed bibliographic metadata for PMID 42290292 at 2026-08-10T18:13:52.268Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42290292-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42290292-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42290292-exenatide-v1
- Content SHA-256: `224f6220933a5e854948f1e0db34eb3d951c778f5d014d92d57c29c9d13d9342`

### Claims and source pins

#### Headline

PubMed record PMID 42290292 ([`pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0`](#source-pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42290292 at 2026-08-10T18:13:52.268Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0`](#source-pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42290292 at 2026-08-10T18:13:52.268Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0`](#source-pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0`](#source-pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0))

### Sources

<a id="source-pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0"></a>
- **PubMed record PMID 42290292 · retained source version 1:2026-07-26:current:c76aab7f7ac027a55f437aec657fb2f53282db71402b3455367d41fbb00610d4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42290292/) (`pubmed-observation-pmid-42290292-2026-07-26-c76aab7f7ac0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42290292." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42290292-exenatide-v1 SHA-256: 224f6220933a5e854948f1e0db34eb3d951c778f5d014d92d57c29c9d13d9342.

---

<a id="pubmed-pmid-42330995-exenatide-v1"></a>

## PubMed record PMID 42330995

> PeptideScanner retained PubMed bibliographic metadata for PMID 42330995 at 2026-07-30T16:14:19.343Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-06-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42330995-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42330995-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42330995-exenatide-v1
- Content SHA-256: `e20fa32bb56029fa23626e25f208795e6c5159909e11956edbb7428faf56b8b5`

### Claims and source pins

#### Headline

PubMed record PMID 42330995 ([`pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97`](#source-pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42330995 at 2026-07-30T16:14:19.343Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-06-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97`](#source-pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42330995 at 2026-07-30T16:14:19.343Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-06-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97`](#source-pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97`](#source-pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97))

### Sources

<a id="source-pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97"></a>
- **PubMed record PMID 42330995 · retained source version 1:2026-06-25:current:2e8558c35d97cfc7191ec587baba189d50dcf63449726c62e89650fdc17a7d1e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42330995/) (`pubmed-observation-pmid-42330995-2026-06-25-2e8558c35d97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42330995." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42330995-exenatide-v1 SHA-256: e20fa32bb56029fa23626e25f208795e6c5159909e11956edbb7428faf56b8b5.

---

<a id="pubmed-pmid-42709517-exenatide-v1"></a>

## Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.

> PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42709517-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-08
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42709517-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42709517-exenatide-v1
- Content SHA-256: `78d4e833caedbe4691182b5486bf5d6b70d146174a32b9215fcbe585501e7dd1`

### Claims and source pins

#### Headline

Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e))

#### Summary

PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e))

#### Paragraph 1

PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e))

### Sources

<a id="source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e"></a>
- **Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction. · retained source version 1:2026-09-08:current:8c8d68644f0e4309bffafab6f38dd66c4112e84053f6d3c64f74fef6e5ae464e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42709517/) (`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42709517-exenatide-v1 SHA-256: 78d4e833caedbe4691182b5486bf5d6b70d146174a32b9215fcbe585501e7dd1.

---

<a id="pubmed-pmid-42709517-exenatide-v2"></a>

## Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.

> PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42709517-exenatide:v2`
- Evidence domain: Literature metadata
- Date in source: 2026-10-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42709517-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42709517-exenatide-v2
- Content SHA-256: `a99f29f672aebf9eb8b718fcdff3acaebeb9f7e87394cab0ec113671a281b9bc`

### Claims and source pins

#### Headline

Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2))

#### Summary

PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2))

#### Paragraph 1

PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2))

### Sources

<a id="source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2"></a>
- **Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction. · retained source version 1:2026-10-30:current:62a63971814bb423fbc37e1b457f5a356652b2fccf219a3ee6390cdcbbab4d60** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42709517/) (`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2`)

### Correction lineage

updated on 2026-11-16: PubMed revised the bibliographic metadata of PMID 42709517, with a metadata revision date of 2026-10-30. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2`](#source-pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2)

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/exenatide.json#pubmed-pmid-42709517-exenatide-v2 SHA-256: a99f29f672aebf9eb8b718fcdff3acaebeb9f7e87394cab0ec113671a281b9bc.

